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Abstract 
Background 
Since recognition of acquired immunodeficiency syndrome (AIDS) in 1981, an 
estimated 60 million people, worldwide, have been infected with HIV, and an estimated 
25 million people have died of AIDS. In Canada almost 50,000 people are believed to be 
HIV positive, and each year over 2000 new infections are reported to the Centre for 
Infectious Disease Prevention and Control (CIDPC). 
It is unknown whether long-term psychotherapy can prevent psychological 
dysfunction in HIV I AIDS patients. 
The objective of this randomized controlled trial (RCT) was to determine the 
impact oflong-term psychotherapy on depression, the primary outcome measure, 
hopelessness, coping skills, and CD4 counts in a group ofHIV positive subjects who 
were heterogeneous in respect to their HIV infection, and level of psychological health. 
Methods 
mv positive adults at a tertiary referral centre were randomly assigned to receive 
either long-term psychotherapy (N=l6), or no psychotherapy with crisis intervention 
(N=14), irrespective of initial psychological health. 
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Results 
The mean age was 30 years, Beck Depression Inventory (BDI) score 22 and CD4 
count (cells/J.!L) 277. At 0, 6 and 12 months, the mean BDI scores were 20, 18 and 26 in 
the control group, compared to 23 (P = 0.34), 13 (P = 0.016), and 9 (P = 0.006) in the 
intervention group. 
Mean Beck Hopelessness Scale scores (BHS) were 1 0, 11 and 13 vs. 10 (P = 
0.968), 7(P = 0.027), and 6 (P = 0.005). 
Coping Inventory for Stressful Situations (CISS) scores were: Task, 52, 53 and 55 
vs. 52, (P = 0.906), 55 (P = 0.654) and 59 (P = 0.214); Emotion, 50, 46, 49 vs. 51, (P = 
0.846), 49 (P = 0.374) and 43 (P = 0.059); Avoidance, 49, 46 and 46 vs. 51 (P = 0.426), 
46, (P = 0.036) and 52 (P = 0.062); Distraction, 25, 23 and 24 vs. 24, (P = 0.708), 25 (P 
= 0.221) and 25 (P = 0.331); Social Diversion, 15, 14 and 13 vs. 15, (P = 0.640), 17 (P = 
0.031) and 17 (P = 0.031). 
CD4 counts were 333, 243 and 346 vs. 232 (P = 0.25), 262 (P = 0.09), and 259 (P 
= 0.764). 
Conclusion 
Long-term psychotherapy ameliorates depression and hopelessness in persons 
living with HIV I AIDS. It may also have a preventative effect. 
Keywords 
randomized controlled trial, psychotherapy, HIV/AIDS, depression, 
hopelessness, HIV prevalence, HIV incidence 
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CHAPTER I 
INTRODUCTION 
1.1 Overview of the Chapter Contents 
Chapter one of this thesis is intended to provide the reader with information 
related to establishing a diagnosis of human immunodeficiency virus (HIV) and acquired 
immunodeficiency syndrome (AIDS), and provide a brief overview of some of the 
clinical manifestations of HIV infection. This chapter also presents a global, Canadian, 
and Newfoundland and Labrador overview of the prevalence ofHIV and AIDS infection. 
Included in this chapter is a summary of the purpose of the Randomized Controlled Trial 
(RCT), which forms the basis of this thesis. 
The intent of chapter two is to provide the reader with information related to the 
provision of psychotherapy. To help accomplish this, brief definitions of some common 
psychotherapies are provided. This chapter discusses the psychotherapeutic approach 
used in the thesis RCT as well as an overview of the literature related to the provision of 
psychotherapy for persons living with HIV/AIDS. Included in this chapter, is information 
related to the prevalence and incidence of depression. A review of the major clinical 
trials related to the thesis RCT primary and secondary outcome measures in patients with 
HIV disease is presented in this chapter. The review covers the period up to the 
commencement ofthe thesis RCT in 1996. 
1 
Chapter three describes the tools used to measure depression, hopelessness, 
coping and CD4 T -cells in the trial subjects. The RCT methodology is also presented in 
this chapter. 
Chapter four provides the baseline descriptions of the trial subjects. This chapter 
includes the results of the analyses of the primary and secondary outcome measures. 
In chapter five the reader is presented with a discussion of the results and 
implications of the RCT findings related to the primary and secondary outcome 
measures. In addition, there is discussion ofthe major clinical trials that were published 
after the start of the thesis RCT. In this chapter strengths and weaknesses of the trial are 
presented as well as implications and recommendations for clinical practice and health 
care provider education. 
1.2 Introduction to the Thesis 
Since recognition of acquired immunodeficiency syndrome (AIDS) in 1981 
among homosexual men in the United States of America (USA) (UNAIDS, 1996) we 
have witnessed emergence of a disease often assigned labels which have contributed to 
both a misunderstanding of the demographics of its victims and an underestimation of the 
magnitude of its global invasiveness. AIDS and its subsequent etiologic label, human 
immunodeficiency virus (HIV), has worn a variety of unique and oftentimes pejorative 
descriptors; a disease whose labels were, and sometimes still are, imbued with prejudice, 
2 
hate, and fear. Its various labels have also provided indications of the ignorance of the 
etiology ofHIV. 
The early 1980s gave us "The Gay Plague" label, which provided a kind of 
comfort and promise of safety to the heterosexual community, by supporting a belief only 
Gays were susceptible and heterosexuals were safe from both HIV and AIDS. Within a 
few years, however, there were noticeably large numbers ofHIV positive diagnoses 
observed in intravenous drug (IV) users and sex trade workers; reinforcing a newer label 
of "gods punishment for queers, whores and junkies" and again providing a misguided 
sense of safety in the general population. Even with an increased diagnosis ofHIV 
among heterosexuals in the Haitian community, pejorative labels attached to this 
community helped blind society to the pervasiveness ofHIV and AIDS. 
In the early 1990s, when HIV had clearly established itself outside marginalized 
communities and into the straight community, a more accurate label of "epidemic" 
became associated with the disease. This newer label more fully implicated the impact of 
HIV on heterosexuals and homosexuals alike, males and females, young and old, rich and 
poor, educated and uneducated, marginalized and not. The world was being prepared for 
the most accurate of the labels assigned to HIV/AIDS. 
By the mid nineties HIV had been fully recognized as a "pandemic" and currently 
HIV /AIDS is the "fourth biggest killer globally" (UNAIDSIWHO, 2001). One of many 
issues in the management ofHIV/AIDS in Canada generally, and in the province of 
Newfoundland and Labrador in particular, is the relatively low numbers of cases of 
HIV/AIDS. It is easier to ignore the virulence of this disease with the numbers of 
3 
HIVIAIDS infections observed in Canada and Newfoundland and Labrador. With an 
estimated 48,800 persons living with HIV I AIDS in Canada, and only 134 in 
Newfoundland and Labrador (Disease Control and Epidemiology Division, Department 
of Community Services of St. John's, Newfoundland, 2001), it may be possible to 
underestimate the physical, emotional and social consequences of HIV I AIDS, especially 
when compared to the impact in places such as sub-Saharan Africa. In that region the 
impact is difficult to ignore when an estimated 28.1 million adults and children are living 
with HIVIAIDS (UNAIDSIWHO, 2001). The main mode of transmission is heterosexual 
contact, almost ensuring increased numbers of seropositive persons. Adding to the main 
mode oftransmission is the fact that 55% of the HIV positive adults are women and this, 
in conjunction with a lack of antiretroviral therapy, ensures an increase in the number of 
children born with HIVIAIDS (UNAIDSIWHO, 2001). 
HIVIAIDS is a chronic debilitating disease that is blind to race, age, geography, 
income, sexual orientation and religion; and has become, according to the WHO, a 
worldwide threat to human health (UNAIDSIWHO, 2001). 
1.3 Laboratory Definition of HIV 
Human immunodeficiency virus (HIV -1) is a human retrovirus containing 
ribonucleic acid (RNA) and an enzyme, reverse transcriptase, to transcribe RNA into 
deoxyribonucleic acid (DNA). HIV is transmitted across the mucocutaneous barrier with 
extension to regional lymph tissue within days of exposure. Within weeks the infected 
4 
individuals experience massive viremia and an acute retroviral syndrome (about 40-70 % 
of cases) accompanied by widespread dissemination and extensive involvement of lymph 
tissue. There is an immune response with partial control ascribed to the cyotoxic T -cell 
response and a humoral response ( seroconversion at 6-12 weeks) within weeks to 
months. About six months to a year after transmission of the virus, the infected individual 
has persistent HIV replication with relatively constant levels ofHIV RNA in the 
bloodstream; and experiences gradual CD4 cell depletion averaging 50/mm3/year over a 
mean of 8-10 years. Eventually there is a massive destruction of the immune system with 
susceptibility to opportunistic pathogens and tumors, particularly when the CD4 count 
falls below 200/mm3 (Bartlet, 1997; Carpenter eta/., 2001). HIV-1 is the causative agent 
in Acquired Immunodeficiency Syndrome (AIDS) (UNAIDS, 1996; Levy 1989). 
In addition, there is a recognized second HIV virus, HIV -2, which is associated 
with a considerably longer clinically latent period than HIV -1 (Markovitz, 1993; 
Carpenter eta/., 2001). This virus, identified in West Africa in the mid 1980s, also results 
in AIDS. Though HIV -1 and HIV -2 share many biologic and genetic characteristics, they 
have regulatory and structural genes that are unique. HIV -1 is closely related to the 
simian immunodeficiency virus (SIV) isolated from a subspecies of chimpanzee; whereas 
HIV -2 is more closely related to an SIV commonly found in the sooty mangaby 
(Carpenter eta/. 2001). Due to the rarity ofHIV-2 infections outside the West African 
region this thesis will focus on the more pervasive and generally referred to form of the 
virus, HIV -1. 
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1.4 Establishing a Diagnosis 
A diagnosis of HIV is generally made through a positive test result from an 
enzyme-linked immunoabsorbent assay (ELISA) screening test to detect HIV-1 and HIV-
2 antibodies in blood. A reactive screening test must be verified by a second test such as 
the Western Blot1• 
The current laboratory definition ofHIV infection (CDCP, 1999; CDCP 
Appendix, 1999) is described in terms of a positive test result on a screening test for HIV 
antibody (e.g., repeatedly reactive enzyme immunoassay), followed by a positive result 
on a confirmatory (sensitive and more specific) test for HIV antibody (e.g., Western blot 
or immunofluorescence antibody test) or a positive test result or report of a detectable 
quantity on any of the following HIV virologic (nonantibody) tests: 
• HIV nucleic acid (deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) 
detection (e.g., polymerase chain reaction (PCR) or plasma HIV- 1 RNA DNA); 
• HIV p24 antigen test; 
• HIV isolation (viral culture). 
In Newfoundland and Labrador, HIV diagnosis is determined in the following 
manner: 
The samples are screened using a highly sensitive enzyme immunoassay antibody (EIA) 
screen test. If a sample tests positive then a second EIA test, with a high specificity, is 
1 A procedure in which proteins separated by electrophoresis in polyacrylamide gels are transferred 
(blotted) onto nitrocellulose or nylon membranes and identified by specific complexing with antibodies that 
are either pre or post-tagged with a labeled secondary protein (Williams & Wilkins, 1995). 
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conducted. If either of these tests is repeatedly reactive for antibodies or yields 
indeterminate results then a Western blot test is conducted. If the Western Blot is 
positive there is a confirmed case ofHIV infection. If the Western Blot is negative then 
no further testing is indicated, unless the person is considered to be at high risk for HIV 
infection in which case repeat testing is recommended in three to six months. If the 
Western Blot test is indeterminate then a repeat test is conducted within 3- 6 months. 
In the case of infants born to HIV seropositive mothers a slightly different 
approach is taken to determine the HIV status. Babies born to seropositive mothers will 
test positive for HIV- antibodies for up to 18 months after birth because of placental 
transfer of maternal antibodies. In this situation a polymerase chain reaction test (PCR), 
which is a molecular test for HIV RNA, can be utilized. This test can confirm a diagnosis 
before the disappearance of maternal antibodies in the baby and can determine if the 
infant has viral genetic material. Another common test used for infants of seropositive 
mothers is the p24 antigen test. 
HIV and AIDS refer to the continuum of the infection, where HIV reflects the 
presence of the virus with or without evidence of immune suppression. In Canada, AIDS 
refers to the presence of an opportunistic infection or other illness indicating immune 
suppression in a person who is not compromised for reasons other than HIV. 
1.5 Sequential Clinical Manifestations of HIV -1 Infection 
Within 2 to 8 weeks of initial infection with the HIV virus between 40 and 70 
percent of persons experience a mononucleosis-like syndrome. During this acute 
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retroviral syndrome stage, infected individuals may experience fever, sore throat, lymph 
node enlargement, rash, arthralgias, fatigue, and headache. These symptoms generally 
last for several days to 3 weeks. Additionally a short-lived maculopapular rash on the 
face and trunk is common. Acute self-limited aseptic meningitis is observed in 10 to 20 
percent of patients. The acute retroviral syndrome varies greatly in both duration and 
severity. During this stage, HIV antibody is generally not detectable and HIV infection is 
detected by plasma HIV RNA or p24 antigen assays (Carpenter et al., 2001). 
In untreated people, the acute retroviral syndrome stage is usually followed by a 
slow nonlinear progression to severe immunodeficiency marked by progressive depletion 
of CD4 cells. Approximately 50 % of untreated individuals develop AIDS within 1 0 
years of HIV infection; 30 % have milder symptoms; and less than 20 % are 
asymptomatic 1 0 years after infection. 
Major life threatening Opportunistic Infections (Ois) seldom occur until the CD4 
cell count is below 200 cells/mm3· At this stage infected individuals are at high risk of 
Ois [e.g., Pneumocystis carinii pneumonia (PCP)] and neoplasms. 
CD4 counts below 50 cells/mm3 indicate profound immunosuppression. HIV 
immunosuppressed individuals frequently experience Ois and neoplasms; most common 
and potentially preventable are cytomegalovirus (CMV) retinitis, toxoplasmosis, and 
disseminated Mycobacterium avium complex (MAC). Ineffective antiretroviral therapy at 
this stage of illness is associated with high mortality within the subsequent 24 to 36 
months. 
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With the substantial improvements in disease management, particularly through 
the introduction of antiretroviral treatments, it is widely believed that, in the presence of 
active treatment, life expectancy more than doubles for HIV infected persons. Recent 
estimates show a decline in mortality since 1995 from 29.4 per 100 person-years to 8.8 
per 100 person-years (Palella, Delaney, Moorman, et al. 1998). In addition to 
Opportunistic Infections (01) and neoplasms, patients may experience a variety of 
dertamologic conditions (Carpenter, Flanigan & Lederman, (2001) (Table 1.1 ). Patients 
may also experience HIV -1 associated dementia complex (HADC), mood disorders and 
HIV wasting syndrome (Brouillette & Citron, (1997). These outcomes vary in terms of 
frequency and severity. Following a diagnosis ofHIV many patients can expect to 
experience a variety of complicating illnesses, many of which are painful and life 
threatening, severely impacting quality of life. 
Table 1.1: Common Dermatologic Conditions in HIV 
Herpes simplex [cold sore or genital herpes] 
Herpes zoster [shingles] 
Staphylococcal folliculitis 
Bacilliary angiomatosis 
Molluscum contagiosum 
Seborrheic dermatitis 
Psoriasis 
Candidal dermatitis 
Table 1.2, adapted from Carpenter et al. (200 1) provides a list of the opportunistic 
infections (01) and neoplasms associated with HIV disease. It also indicates both the 
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CD4 cell count levels at which the various Ois and neoplasms generally occur, as well as 
estimates of their frequency of occurrence. Infections may reoccur or progress during the 
course of disease. 
Table. 1.2: CD4 Cell Counts and Frequencies of AIDS Associated Ols and 
Neoplasms 
CD4 Count 
C ll I 3 e smm 
200-100 
<100 
<100 
<100 
200-100 
200-100 
<100 
<100 
500-200 
500-200 
<100 
<100 
500-200 
500-200 
200-100 
<100 
<100 
<100 
0 . t' I fi Jpportums 1c n ect10n or N eopJasm F 
Protozoan 
• Pneumocystis carinii pneumonia (PCP) 
• Toxoplasma gondii encephalitis 
• Cryptosporidium parvum enteritis (> 1 month) 
• Isospora belli enteritis (> 1 month) 
Fungal 
• Disseminated histoplasmosis 
1 
• Disseminated coccidioidomycosis 
1 
• Candida esophagitis 
• Cryptococcus neoformans meningitis 
Bacterial 
• Active Mycobacterium tuberculosis infection (TB) 
• Recurrent bacterial pneumonia 
• Disseminated Mycobacterium avium complex 
(MAC) 
• Recurrent Salmonella septicemia 
Viral 
• Chronic(> 1 month) mucocutaneous herpes 
simplex virus infection 
• Chronic(> 1 month) esophageal herpes simplex 
virus infection 
• Progressive multifocalleukoencephalopathy (JC 
virus) (PML) 
• Cytomegalovirus retinitis (CMV) 
• Cytomegalovirus esophagitis 
• Cytomegalovirus colitis 
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requency 
20-60 
5-25 
2-10 
2-10 
0-20 
0-20 
15-20 
3-5 
2-20 
15-20 
20-35 
2-10 
40-70 
40-70 
2-3 
20-35 
4-8 
4-8 
Table. 1.2: CD4 Cell Counts and Frequencies of AIDS Associated Ols and 
Neoplasms (Continued) 
CD4 Count 
C ll I 3 e smm 0 . . I fi Jpportumst1c n ectwn or N eop.asm F requency 
Helminths2 Rare 
<100 • Strongyloidiasis (disseminated beyond the 
gastrointestinal tract) 
Neoplasms 
• Kaposi's sarcoma (person< 60 years old) 
500-200 mucocutaneous 15-30 M3 
200-100 visceral 3-8M 
500-200 • Invasive carcinoma of the cervix 1-2 F
4 
• High-grade, B-cell non-Hodgkin's lymphoma
2 
200-100 
• Undifferentiated non-Hodgkin's lymphoma 2-5 
• Immunoblastic sarcoma2 
<100 
• Primary brain lymphoma 3-6 
I. Endemic areas 
2. Not specific to CD4 count. 
3. Usually seen in men. 
4. Only seen in women (Related to human papilloma virus.) 
The frequency of all opportunistic infections and neoplasms decrease with viral 
control and immunologic reconstitution following effective anti-retroviral therapy. Many 
of the infections can be managed or prevented with specific antimicrobial prophylaxis. 
The neoplasms must be managed through specific cancer protocols but increased survival 
is dependent on HIV control (Palella, Delaney, Moorman, et al. 1998; Carpenter, 
Flanigan & Lederman, (2001). 
1.6 Implications and Understanding ofCD4 T-lymphocytes and Viral Load 
The generation of an effective immune response is highly dependent on the 
presence and type of white blood cell known as the lymphocyte. Lymphocytes are one of 
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the white blood cells produced in bone marrow. They are small, featureless cells with few 
cytoplasmic organelles and condensed nuclear chromatin. Lymphocytes require contact 
with a foreign antigen to trigger their proliferation and differentiation into their 
specialized functions. Lymphocytes possess unique antigen-binding cell surface 
receptors, and can mediate the defining immunological attributes of specificity, diversity, 
memory, and selflnonselfrecognition. 
The two major populations of lymphocytes that circulate in the blood and reside 
in various lymphoid organs are T lymphocytes and B lymphocytes. T lymphocytes 
mature in the thymus and are responsible for the cell-mediated arm of the immune 
response, whereas B lymphocytes mature in the bone marrow and, upon encounter with 
specific antigen, produce antibody molecules which mediate the humoral arm of the 
immune response. Helper T cells and cytotoxic T cells are two well-defined 
subpopulations ofT lymphocytes, and are distinguished by the presence of CD4 
membrane receptors (CD4+) on their surfaces for helper cells and CDS membrane 
receptors (CDS+) for cytotoxic cells. When CD4+ T lymphocytes are activated they 
secrete various growth factors called cytokines, which play a critical role in activating the 
various cells that participate in immune responses. The generation of both antibody-
mediated and cell-mediated immunity depends on the activation of CD4+ helper T 
lymphocytes. These cells function as the central control element for most immune 
responses. The human immunodeficiency virus is able to infect human cells that express 
the CD4 receptor on their surface. HIV binds to the CD4 receptor, and with the aid of a 
co-receptor, fuses with the cell membrane gaining entry into the cell commencing a 
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process that destroys the CD4 cell. For more detailed information on CD4 T cells see 
Janeway et al. (1999), or a similar immunobiology text. The normal range for CD4 T 
cells is 700-1100 cells/mm3 (Hannet et al., 1992). 
Viral load (VL), measured in copies/mL, is a measurement of the levels ofHIV 
RNA in blood plasma of an HIV -infected individual. Like the CD4 cells, it is used both 
as a marker of disease severity and a guide to therapy. In conjunction with CD4 cell 
counts, virus load measures provide prognostic information, which is used to help 
determine when to implement and when to change antiretroviral therapy. Table 1.3 
extracted from Carpenter eta!. (2001) effectively demonstrates the relationship ofCD4 
cell counts and VL levels to disease progression. 
Table 1.3: Guidelines for the Initiation of Antiretroviral Therapy in HIV+ Patients 
Clinical Category CD4+ T Cell Count and HIV RNA Recommendations 
Symptomatic (AIDS, Any values Treatment generally 
thrush, unexplained recommended 
fever) 
Asymptomatic CD4+ T cells < 350 mmj or HIV RNA> Treatment recommended 
30,000 copies/mL 
Asymptomatic CD4+ T cells between 350 and 500 and Treatment should be 
HIV RNA between 10,000 and 30,000 considered based on prognosis 
for disease free survival. 
Asymptomatic CD4+ T cells > 500 mmj and HIV RNA < Most clinicians would delay 
10,000 copies/mL therapy and observe; however 
some would treat under certain 
conditions. 
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1. 7 Global profile of HIV and AIDS 
The goal of the following section of this thesis is to present a numerical 
representation of the Global, Canadian and Newfoundland and Labrador face of 
HIV/AIDS, for both the period 1996, when this Randomized Controlled Trial (RCT) was 
begun, and the current presentation of the disease, determined from the 2001 HIV I AIDS 
estimates. Where appropriate, cumulative estimates ofHIV/AIDS data are presented 
first. These data will be followed by estimates specific to the time periods under 
discussion, 1996 and 2001. Where data are available and the distinction between HIV 
and AIDS is considered appropriate for understanding issues, data will be presented 
separately for the two conditions. 
The UNAIDS/WHO 2001 AIDS epidemic update presents a disturbing picture of 
the twenty-first century presence ofHIV/AIDS. The global prevalence rate for adults is 
1.2 %, with rates for various countries ranging from a low of 0.1 %to a high of 8.4 %. 
Since its discovery an estimated 60 million people have been infected with HIV and an 
estimated 25 million people have died of AIDS (UNAIDS/WHO, 2001). 
If we take into account the number of people estimated to have been infected with 
HIV and to have died from AIDS prior to 1996, we see a reasonably clear picture of the 
changing face ofHIV/AIDS from 1996 to 2001 (Table 1.4). 
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Table 1.4: Comparisons of Global Estimates ofHIV/AIDS Infection -1996 and 2001 
1996 2001 
Males Females Children Total in Males Females Children 
millions 
HIV 
prevalence 12.6mil. 9.2mil. 830,000 22.6 19.6mil. 17.6 mil. 2.7 mil. 
HIV 400.000 3.1 2.5 mil 1.8mil. 800,000 
incidence 1 
AIDS deaths 650,000 470,000 350,000 1.5 1.3mil. 1.1 mil. 580,000 
per yr. 
1 UNWHO 1996 report does not provide estimates for males and females separately but reports 
almost half the 2. 7 million new infections occur in women. 
2 Figures do not tally due to UNAIDS/WHO rounding. 
Total in 
millions 
40.0 
5.0 2 
3.0 
The global picture ofHIV/AIDS in 2001 reveals an estimated 40 million people, 
worldwide, were living with HIV I AIDS, an increase of 17.4 million from the 1996 
estimates. Ofthis total population, males accounted for 19.6 million, females 17.6 
million, and children 2.7 million. These figures represent an increase of7 million, 8.4 
million, and 1.9 million respectively compared to the 1996 estimates. The number of 
females with HIV/AIDS increased by 48 % and women, currently, account for 44 % of 
global HIV/AIDS infection. Similarly, reports ofthe number ofnew cases ofHIV/AIDS 
demonstrate an increase from 1996 figures compared to 2001, 3.1 million vs. 5.0 million 
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respectively. The number of deaths attributed to AIDS doubled in 2001 compared to the 
1996 figures; 3.0 million vs. 1.5 million (Table 1.4). 
Not only are millions oflives lost annually to HIV/AIDS, but millions of new 
infections also occur each year. Over a third of people living with HIV are aged 15 to 24 
and it is believed by the UNAIDS and WHO that most of them are unaware they carry 
the virus (UN AIDS WHO, 2001 ). It is reasonable to conclude that HIV has not only 
severely impacted the quality of life of people worldwide, but is becoming increasingly 
invasive. 
1.8 Canadian Profile of HIV and AIDS 
The following profile of HIV in Canada has been derived from Health Canada 
Population and Public Health Branch publications and reflects the most current 
government data available. The statistical information has been derived primarily from 
the Canada Communicable Disease Report (CCDR) - Volume 26-23, December 2000, 
the HIV I AIDS Epidemiology Update, May 2001 and the HIV and AIDS in Canada 
Surveillance Report to December 31 , 2001, (April2002). It should be noted that data 
used to arrive at numbers related to HIV/AIDS in Canada are extracted from surveillance 
data reported to the Centre for Infectious Disease Prevention and Control (CIDPC) to 
December 31,2001 . Additionally, utilizing reported positive HIV tests and AIDS cases 
underestimates the number of persons living with HIV/AIDS. The inaccuracies of this 
kind of reporting are reflected in that the data represent only a portion of the true number 
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of HIV positive individuals; specifically those who come forward for testing, are 
diagnosed, and are reported as HIV positive to CIDPC. Data collected as a function of 
reported positive results will not capture cases of HIV that have not been tested, and will 
reflect inaccuracies due to underreporting, delayed reporting, and changes in testing 
behavior, such as who comes forward for testing. In addition, the number of positive test 
reports in a given year is not an estimate of the number of new infections occurring in 
that year because most of the individuals would have been infected in previous years and 
the majority of individuals newly infected in that year will be diagnosed years later. The 
CIDPC estimates 15,000 Canadians are HIV positive but unaware of their infection 
because they have not come forward for testing (Division of HIV I AIDS Epidemiology 
and Surveillance, Bureau ofHIV/AIDS, STD and TB, April2000). 
Less than 0.01 % ofHIV in Canada is attributed to positive test results on children 
(defined as under 15 years of age). For the period January 1996 to December 2001, 264 
new test results were reported, and only 15 cases in 2001. Additionally, the number of 
cases ofHIV positive children has been declining since 1995 (Health Canada HIV and 
AIDS in Canada, 2002). With respect to statistics involving HIV/AIDS infection in 
children, only very general information will be provided, and this thesis will generally 
report Canadian demographics in terms of males and females and the numeric values for 
each will include children under 15 years of age. This decision was taken primarily 
because the focus of this thesis was HIV infection in adults. This decision was reinforced 
by the relatively small numbers of reported cases ofHIV infection in children in Canada, 
statements by Health Canada that HIV test reports for children contain inaccuracies in 
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both data collection and reporting, and statements by Health Canada that there is a lack of 
uniformity in provincial reporting of cases involving persons under age 15. 
Except where specified the information in the following sections, unless 
otherwise indicated, has been extracted from Canadian HIV surveillance data and covers 
the period to December 31 , 2001. The estimates are calculated utilizing the number of 
reported HIV positive test results. The national prevalence information, however, will be 
based on estimates calculated by CIDPC. With this in mind, a reasonable representation 
ofthe number of Canadians living with HIV/AIDS in both the 1996 time period and the 
present can still be examined. 
Canada began formal collection and analysis ofHIV/AIDS related data in 
November of 1985. In 1996, at the beginning of this RCT, there were an estimated 
40,100 Canadians living with HIV/AIDS. The vast majority, 35,500, were males, with 
females accounting for 4,600 cases. In 1999, the latest period for which Health Canada 
provides prevalence and incidence figures, there are an estimated 49,800 people living 
with HIV I AIDS in Canada, with males accounting for over 86.3 %of cases (Table 1.5). 
The adult prevalence rate is 0.3 %. 
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Table 1.5 Comparisons of Canadian Estimates ofHIV/AIDS -1996 and 19991 
1996 1999 
Males Females Total Males Females 
HIV prevalence 35,500. 4,600 40,1002 43,000. 6,800 
HIV incidence 3,250 950 4,200 3,270 920 
1 Canadian prevalence and incidence related estimates are only available to the end of 1999. 
2 Includes those living with AIDS. 
In 1996, Health Canada estimated 4,200 new HIV infections, with males 
accounting for 77.4% and females 22.6% of cases. There was little change in the 
estimates of new infections for the period 1999 (Table 1.5). 
Total 
49,8002 
4,190 
At the start of this clinical trial there was a cumulative total of approximately 
29,750 males with HIV positive test reports, making up 88.5% ofHIV infections. 
Females totaled 3,881 positive test reports comprising approximately 11.5% ofHIV in 
Canada. As of 2001; the cumulative number of HIV positive test results was 50,259. Of 
this number 49,562 are adults, and 697 children under 15. Currently, adults comprise 
almost 99% ofthe cumulative number of positive test results. There was a decrease of 
2.9% in the 2001 proportion of males with positive test results compared to 1996 (Table 
1.6). In 2001, 85.6 percent of all adult tests results were found in males, with females 
accounting for 14.4 %. Over 72 % of adult HIV infection is seen in persons between 20 
and 39 years old. 
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Table 1.6: Comparisons of Canadian HIV/AIDS Surveillance Data -1996 and 2001 
1996 2001 
Males Females Total Males Females Total 
Cumulative Positive 29,750 3,881 38,593 I 38,101 6,411 50,259 2 
HIV tests 
Cumulative AIDS 14,488 1136 15,624 16,519 1,501 18,026 J 
cases 
Cumulative AIDS 11,321 12,538 
deaths 4 
HIV incidence 1,988 541 2,785 ~ 1,601 535 2,172 b 
AIDS incidence 939 137 1,076 184 35 22C 
AIDS deaths 1042 81 
per year 4 
1 The total for males plus females included 4962 results with gender unreported. 
2 The total for males plus females included 5747 results with gender unreported. 
3 Includes 6 cases where gender is unreported. 
4 CIDCP did not provide AIDS deaths by gender. 
5 Total includes 256 cases where gender is unreported. 
6 Total includes 36 cases where gender is unreported. 
7 Total includes 2 cases where gender is unreported. 
In 1996, 1,988 new cases ofHIV were reported for males and 541 new positive 
tests for females. By the end of 2001, 2,172 new cases of HIV were reported to CIDPC 
(Table 1.6). There was a 24 % increase in the numbers of persons living with HIV in 
Canada between 1996 and 2001. It should be noted, however, this increase reflects not 
only new diagnoses but also a decline in AIDS deaths due to improved treatments. 
However, despite concentrated efforts through health updates, the media and education 
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programs, 14,168 new positive results were reported during this period. Since 1996 there 
has been a 21.8% drop in the annual numbers of new diagnosis and the number of new 
cases has remained relatively constant (Table 1.7). 
Table 1.7: Annual Number of Reported New HIV Diagnosis -1996 to 2001 
1996 1997 1998 1999 2000 2001 
Males 1,982 1,781 1,746 1,653 1,557 1601 
Females 540 457 493 545 494 535 
Total1 2,778 2,537 2,322 2,240 2,119 2172 
1 Males plus females is less than the grand total due to test reports with gender umeported. 
Males continue to be the largest group with positive HIV tests, though a 
disturbing statistic is the increase in the annual percentage of females with positive test 
results. Between 1985 and 1994 females represented only 9.9% of the positive test 
results but constitute 25% of adult positive results since 1999. 
We have witnessed a steady increase in the proportion of positive test results from 
heterosexuals, who traditionally represented 7.5% from 1985 to 1994 and now account 
for 32.8 %. 
Another trend is the decline in the proportion ofHIV positive test results for men 
who have had sex with men (MSM). Before 1994, this group accounted for 74.7% of 
HIV infection. A decline to 36.8 % from 1997 to 1999 has been observed. This decline, 
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however, has been followed by an increase to 41.8% in 2000 and a decrease to 36.6% 
for 2001. 
In 1996 injecting drug use (IDU) accounted for 33.7% ofnew cases ofHIV 
infection, but currently accounts for 24.6 % of new cases. 
Given that 25 % of HIV test reports provide ethnicity information, in combination 
with the fact that ethnicity data for positive test results was really only available since 
1998, only limited observations can be made regarding HIV and ethnicity. What can be 
concluded, with caution, is that 64.2% ofHIV positive test results are seen in whites, 
17.7% aboriginal persons, and 18.1 %in non-white non-aboriginal persons. In the black 
population 74.7% of infection is attributed to heterosexual contact and more than 50% 
of these HIV infections are associated with infection occurring outside Canada. As a 
consequence, conclusions regarding HIV and ethnicity need to be considered in lieu of 
the contribution to the numbers of HIV infections directly related to immigration. 
Since the beginning ofthe epidemic in the early 1980s, 18,026 AIDS cases have 
been reported to CIDPC. Adult males make up the largest proportion of cumulative AIDS 
cases at approximately 92.2 %, however, there is an observed overall decline in the 
number of males with AIDS. The proportion for adult females has risen from 8.3 % at the 
start of 1996 to a high of 16.2 % in 1999. Currently, 2001 , the rate for adult females is 
15.7 %. Over 40% of the annually reported AIDS cases are persons between 30 and 39 
years of age. 
In 1996, the cumulative total of reported cases of AIDS was 15,624, with males 
accounting for 14,488 and females 1136. The cumulative number of reported AIDS cases 
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for 2001 revealed an increase of 2,402 cases. Adult males totaled 16,519 and adult 
females 1,501 (Table 1.6). There were 221 cases of AIDS reported in 2001, compared to 
a total of 1,076 new cases of AIDS in 1996 (Table 1.6). 
The proportion of reported AIDS cases attributed to heterosexual transmission has 
been increasing since 1996 and reached a level of35.6% in 2001. 
The proportion of AIDS cases in the category MSM has steadily declined up to 
1996. Despite fluctuations in the proportions between 1996 and 2000, estimates for 2001 
indicate 44.6% of AIDS cases can be attributed to this category. 
The proportion of AIDS cases associated with IDU has risen steadily from 2.3 % 
between 1979 and 1991 to 29.1% in 1999. It currently is calculated to represent 14.4 % 
of AIDS cases. 
Whites have historically represented the largest proportion of reported AIDS 
cases in Canada, however, the proportion of whites declined from 82% at the start of the 
research project in 1996 to 66.0% in 2001. The decrease amongst whites is contrasted to 
the increase among racial minorities. In 2001, 33.9% of AIDS cases were seen in ethnic 
groups compared to 17.9% in 1996. Aboriginals make up 2.8% and Blacks make up 2 
%of our population yet these two groups represented 13.4 and 7.3% respectively of 
AIDS cases in Canada in 2001. Though only 5% of AIDS cases are attributed to Asians 
the cases in this population have been steadily increasing since 1996 from 2.4 to 5.0 %. 
A more detailed breakdown of ethnic status of AIDS in Canada is shown in Table 1.8. 
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Table 1.8: Canadian AIDS Ethnicity 2001 
White Black Aboriginal Asian Latin American Other/not 
reported 
66.0% 13.4% 7.3% 5.0% 2.4% 5.9% 100% 
There were an estimated cumulative total of 11,321 deaths attributed to AIDS by 
the end of 1996. Deaths, in Canada, due to AIDS accounted for a minimum of 12,538 in 
2001, an increase of 1217 deaths {Table 1.6). 
The total number of reported AIDS cases per year has declined over the past 1 0 
years from 15 56 cases in 1991 to 221 in 2001. A similar pattern has been observed in 
AIDS deaths, particularly since 1996, where number of deaths has declined from 1,042 in 
1996 to 81 in 2001. The most likely explanations for this decrease are use of prophylactic 
treatment of opportunistic infections and development of effective antiretroviral 
treatments, which have slowed or prevented the progression from HIV to AIDS. 
Additionally, it is felt by agencies such as Health Canada (Health Canada, 2000) that 
increased underreporting and reporting delays may explain some of the decline of AIDS 
cases in Canada. 
Particularly relevant to this thesis are the implications for psychotherapy as a 
result of increased life expectancy of persons infected with HIV. With lifetime estimates 
of the prevalence of depression as high as 30 %, and prevalence of depression in persons 
living with HIV estimated to be higher than the general population, there is a need for 
interventions aimed at improving psychological well being of persons living with HIV 
and AIDS. 
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1.9 Newfoundland and Labrador Profile of HIV and AIDS 
The following information was obtained from the Disease Control and 
Epidemiology Division, Department of Health and Community Services of St. John' s, 
Newfoundland and Labrador, (2001) and Health Canada, Population and Public Health 
Branch, (2002). 
In 1996, ofthe 175 recorded cases ofHIV/AIDS, 79.4% (139) were males and 
20.6 % (36) females. This differs from the national figures for 1996 where women 
represented only 11.5 %of positive test results and males 88.5 %. Since Newfoundland 
and Labrador began collecting HIV and AIDS surveillance data in 1984, 210 HIV 
infections have been reported. This figure represents 0.4% of the Canadian cumulative 
positive tests reports, though Newfoundland and Labrador accounts for only .016 % of 
the population of Canada. Males accounted for 77.6% (163) and females 22.4% (47) of 
cases ofHIV (Table 1.9). Again, these values are different than the national percentages 
where males account for 88.5% and females account for 11.5% ofHIV infections. 
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Table 1.9: Newfoundland and Labrador HIV/AIDS Surveillance Data 1996 and 
2001 
1996 2001 
Males Females Total Males Females Total 
Cumulative 
positive HIV tests 139 36 175 I63 47 210 
Cumulative 
AIDS cases 55 II 66 67 I8 85 
Cumulative 
AIDS deaths 1 76 
HIV incidence 8 2 10 5 0 5 
AIDS incidence 5 2 7 2 0 2 
1 Information related to AIDS deaths by year is unavailable. 
There were 10 new reports in 1996 with males accounting for 8 cases and females 
2. From 1996 to December 31 , 2001 there was an increase of35 positive test results. Five 
reported positive HIV test results occurred in 2001 alone, all attributed to males (Table 
1.9). 
By 1996, 66 cases of AIDS had been reported in Newfoundland and Labrador 
with males making up 83.3% (55) of the reports and females 16.7 % (11). During this 
same period the national percentages for AIDS were 92.7 % for males and 7.3 % for 
females. By December 31, 2001 , there was an increase of 19 cases of AIDS, bringing the 
total of reported AIDS cases in Newfoundland and Labrador to 85. Of the 85 cases, males 
make up 78.8% (67) and females 21.2 % (18) (Table 1.9). During this same period the 
national percentages for AIDS was 85.3 % attributed to males and 14.7% to females. 
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In 1996 there were 7 new diagnoses of AIDS, with males totaling 5 cases and 
females 2. There were 2 new diagnoses of AIDS in 2001 , with both in males (Table 1.9). 
From the period 1987, when the first Newfoundland and Labrador AIDS deaths 
were recorded and since reporting had begun in 1984, a total of 62 deaths have been 
attributed directly to AIDS. Ofthe above 210 HIV positive cases 76 are known to have 
died, with 13 having died elsewhere or from causes other than AIDS. No information is 
available for one of the deaths (Table 1.10). 
Table 1.10: Cumulative Deaths Among Newfoundland and Labrador AIDS Cases to 
December 2001 
NF AIDS cases with deaths attributed to AIDS Males 52 
Females 10 
Sub Total 62 
NF AIDS cases with deaths occurring outside NF or attributed 13 
to factors other than AIDS 
NF AIDS case lost to follow-up 1 
TOTAL 76 
Currently, there are an estimated 134 people in Newfoundland and Labrador 
living with HIV/AIDS. In 1996, some 70 patients were followed routinely by the HIV 
team. Presently, approximately 90 persons living with HIV/AIDS are treated through 
three infectious disease (ID) clinics located in the St. John's, Carbonear, and Comer 
Brook regions of the province. 
Based on positive test reports for Newfoundland and Labrador and Labrador, 44 
HIV seropositive individuals do not receive routine care through the ID clinics. There are 
several reasons for the differences in estimates of infections versus numbers of patients 
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routinely treated. Several patients are treated outside the province because of their fears 
surrounding confidentiality, some patients are seasonal workers and work several months 
outside Newfoundland and Labrador and Labrador, three patients reside in other 
provinces though their treatment is managed from St. John's, two patients reside in the 
US but return annually to Newfoundland and Labrador for treatment, several patients 
were diagnosed in Newfoundland and Labrador but live outside the province, a few 
patients refuse treatment, and some of the HIV positive individuals have moved and their 
whereabouts are unknown. 
1.10 Purpose of the Study 
While the prognosis and pharmacological treatment for patients with HIV I AIDS 
is well documented, the impact of the disease on the individual's psychological well-
being is less well-known. Members of the HIV clinical team at the Infectious Disease 
Clinic in St. John's have documented that both symptomatic and asymptomatic HIV-
positive patients report frequent feelings of depression and hopelessness and on many 
occasions have requested psychological intervention to assist in dealing with these 
emotions. These feelings were often exacerbated due to the negative reaction of 
communities within the province to individuals living in their midst with AIDS/HIV. 
Though, the number ofHIV/AIDS patients in Newfoundland and Labrador may 
appear small in comparison to Canada and the world, the impact on many individuals and 
communities has been substantial. Early on, the stigma of HIV and AIDS was so 
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punishing, that patients dying of AIDS pleaded with health providers to say they were 
dying of cancer or pneumonia. Many patients, even during hospitalization with AIDS, 
told family members diseases other than AIDS were responsible for their illness. One 
gentleman, upon the death of his brother, pleaded to have the primary diagnosis of AIDS 
be kept secret so that he and the rest of the family would still be accepted in their 
community. In another community, a financially successful family was forced to accept 
social assistance because the local people would no longer purchase services from a man 
whose child had HIV. Another woman buried her two sons, both in their thirties; her 
grief was in no way trivial. In another community, the funeral of one of its infants was 
followed by the funeral of his young father, and both have left behind a wife/mother also 
infected with HIV. When research demonstrated the high prevalence of HIV in women 
from the Conception Bay North (CBN) region, the national media labeled this area the 
"AIDS capital ofNewfoundland and Labrador." Some members of these communities 
felt so ashamed when they had to say they lived in the area that they claimed to be from a 
different region, rather than risk the social ostracism that could accompany residing in 
CBN. The labeling of the community caused the Red Cross to suspend blood donations 
from CBN, increasing both peoples' embarrassment and the negative national publicity. 
Currently, at least one HIV positive individual still fears the AIDS label, and claims to 
friends and strangers alike to be dying of cancer. These are only a few of the stories 
associated with HIV and AIDS and many more stories of shame and despair have been 
heard and told throughout this province. 
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Not every outcome associated with a diagnosis ofHIV/AIDS has resulted in 
isolation and ostracism; and with time, experience, and education there has been an 
increased sensitivity to the plight of living with HIV and AIDS. In many families and 
communities tremendous love and support was provided to persons infected and affected 
by HIV. Some people continue to provide, supportive care and financial assistance to 
patients and their caregivers to help cope with the burden ofHIV disease. Despite this 
support, the grief is undeniable, as communities throughout this province cope with HIV 
infection and bury citizens who have succumbed to AIDS. 
This trial was undertaken to investigate whether the provision of scheduled 
psychotherapy, incorporated into HIV disease management, would lead to a decrease in 
feelings of depression and hopelessness in patients living with HIV infection. Before this 
RCT was undertaken, patients were referred for a psychotherapeutic intervention when 
either of the HIV infectious disease specialists felt they appeared severely depressed or 
when they were examined in a hospital emergency department as a result of a suicide 
attempt or they threatened to commit suicide. The aim of the study reported in this thesis 
was to compare the effectiveness of this approach, which is referred to as "crisis 
intervention", to a model where patients received psychotherapy independent of 
measures and observations of their psychological well-being. 
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1.11 Study goals 
It was within the social context discussed above, and an effort to better understand 
how to effectively treat the psychological impact on individuals living with HIV I AIDS, 
that this study was undertaken. Prior to start ofthis RCT in 1996, there was little research 
evidence related to the provision of psychotherapy to HIV I AIDS patients for the 
management of depression, and no evidence could be found that examined the effect of 
long-term psychotherapy on persons living with HIV disease. The bulk of research 
examined the impact of providing counselling related to safe sex practices and disease 
disclosure as well as suggested a role for support groups for persons infected and affected 
by HIV disease. It was clear from the literature that psychosocial interventions reduced 
the distress associated with confirmation of a diagnosis of HIV I AIDS and that pre and 
post-test counselling should be a part of the routine management ofHIV testing. 
Extensive research also examined the role of psychotherapy in changing risk 
behaviors of HIV infected persons. Again, there was evidence that psychotherapy might 
be beneficial in reducing risk behaviors in high-risk groups. 
Much of the research investigating the role of psychotherapy was conducted 
using gay or bisexual males, patients who had a diagnosis of depression, and patients who 
were HIV asymptomatic. In addition, the studies used small numbers of subjects. No 
studies could be found examining the effects of the provision of long-term psychotherapy 
in a sample of subjects who were heterogeneous in respect to the mechanism of HIV 
infection, gender and level of psychological health. 
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The RCT reported in this thesis was initiated in 1996, by the author ofthis thesis, 
to determine whether long-term psychotherapy can prevent psychological dysfunction in 
HIV I AIDS patients. This researcher wished to look at the effects of providing 
psychotherapy for a minimum of six months to a diverse group of persons living with 
HIV/AIDS. The objective was to determine the impact oflong-term psychotherapy on 
depression, the primary outcome measure, as well as the secondary measures of 
hopelessness, coping skills and CD4 cell counts. The subjects for the trial were a group 
of HIV positive patients who were heterogeneous in relation to their HIV infection and 
level of psychological health. The study results have important implications for 
psychotherapy in the management ofHIV disease. 
1.12 Research Questions 
The primary outcome measure in the RCT discussed in this thesis was the effect 
on depression scores, measured by the Beck Depression Inventory, in HIV positive 
persons receiving psychotherapy of six months duration. The question under 
investigation can be represented in the following way: 
• In persons living with HIV disease, does the provision of six months of 
psychotherapy lead to less depression, as measured by the Beck Depression 
Inventory, compared to a crisis intervention only model of psychotherapy 
delivery? 
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In addition to the primary question, several secondary outcome measures were of 
interest to this researcher. These are reflected in the following questions: 
• In persons living with HIV disease, does the provision of twelve months of 
psychotherapy lead to less depression, as measured by the Beck Depression 
Inventory, compared to a crisis intervention only model of psychotherapy 
delivery? 
• In persons living with HIV disease, does the provision of six and twelve 
months of psychotherapy lead to less hopelessness, as measured by the Beck 
Hopelessness Scale, compared to a crisis intervention only model of 
psychotherapy delivery? 
• In persons living with HIV disease, does the provision of six and twelve 
months of psychotherapy lead to improved coping skills, as measured by the 
Coping Inventory for Stressful Situations, compared to a crisis intervention 
only model of psychotherapy delivery? 
• In persons living with HIV disease, does the provision of six and twelve 
months of psychotherapy lead to an increase in CD4 T -cell counts compared 
to a crisis intervention only model of psychotherapy delivery? 
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CHAPTER2 
PSYCHOTHERAPY- AN OVERVIEW 
2.1 Increasing Role for Psychotherapy 
In the past few decades psychotherapy has played an increasing role in the 
management of a number of chronic illnesses. Health care providers and patients report 
improved clinical outcomes when the patients' psychological well-being is addressed as 
part of the treatment protocol. In fact, evidence of the attention being paid to 
psychosocial aspects of health care are seen in the increasing number of clinical trials that 
examine quality of life outcome measures. Many experts point to a destigmatization of 
psychotherapy (O'Connor & Yalom, 1997). Irvin D Yalom, professor emeritus of 
Psychiatry, Stanford University emphasized the enhanced role of psychotherapy in the 
last decade of the twentieth century: "Psychotherapy was becoming more mainstream, 
more available, and more acceptable to larger segments of the American public" 
(O'Connor & Yalom, 1997) (p. ix). Yalom also speaks of a growing intolerance by 
society of the "noxious long term effects" of trauma and an increasing demand from the 
public for access to counselling facilities and for the provision of adequate counselling 
services in health care plans (O'Connor &Yalom, 1997) (p. x). Numerous experts and 
professional associations in the field of psychotherapy are also echoing this need for an 
increased role for psychotherapy in the management of chronic diseases (Gabbard, 1994; 
Shea 1998; O'Connor & Yalom, 1997). 
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2.2 Defining psychotherapy 
Definitions and descriptions of psychotherapy vary according to the different 
conceptual frameworks used by different therapists. The definitions provided here are 
working definitions extracted from the texts: Standards and Guidelines for the 
Psychotherapies (Cameron, Ennis & Deadman (eds.), 1998) and Psychodynamic 
Psychiatry in Clinical Practice, The DSM-IV Edition (Gabbard, 1994). In the search for a 
definition of psychotherapy, one discovers there are at least as many definitions of 
psychotherapy as there are therapeutic approaches. Wolberg (1977), reviewed thirty-
seven definitions of psychotherapy. He provides the following composite definition: 
"Psychotherapy is the treatment, by psychological means, of problems of an 
emotional nature in which a trained person deliberately establishes a professional 
relationship with the patient with the object of(1) removing, modifying, or 
retarding existing symptoms, (2) mediating disturbed patterns of behavior, and (3) 
promoting positive personality and development" (p. 3). 
Organizations, such as the Canadian Psychiatric Association (CPA) and the Ontario 
Hospital Insurance Plan (OHIP), also provide very reasonable working definitions of 
psychotherapy (Cameron et al., 1998). A drawback in their definitions is the emphasis of 
delivery of psychotherapy by a physician rather than "suitably trained person" seen in the 
more general framework. Bloye and Davies (1999), simply define psychotherapy as a 
treatment that manages psychological symptoms by using the professional relationship 
between a patient and a therapist to change feelings, cognition, and behavior (p. 121 ). 
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Landau (1986), also recognizes the role of a "suitably trained person" in his more 
detailed definition of psychotherapy. His definition will be used in this manuscript for its 
informative content and because it does not limit usage of psychotherapy by the inclusion 
of physician as therapist: 
"Any form of treatment for mental disorders or emotional disturbances in 
which a suitably trained person establishes a professional relationship with an 
identified patient for the purpose of removing or modifying symptoms of the 
disorder, or of promoting character growth and development so as to strengthen 
the patient's ability to cope with the problems ofliving. The relationship 
established between patient and therapist is used to influence the patient to 
unlearn old, maladaptive patterns and to learn and test new approaches. 
Psychotherapy includes guidance, counselling, psychoanalysis, behavior therapy, 
conditioning, hypnotherapy, and all other forms of treatment in which the major 
technique employed is communication, rather than drugs or other somatic agents." 
(p. 2348). 
2.3 Brief Descriptions of Some Common Psychotherapies 
The following section is intended to provide a general understanding of 
psychotherapy through brief descriptions of some common orientations, as well as 
descriptions directly related to the orientation ofthe psychotherapy provided in this RCT. 
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There are numerous forms of psychotherapy, however, they can be abstracted into four 
overlapping, heterogeneous orientations: psychodynamic, cognitive/behavioural, 
strategic/systems, and experiential (Cameron et al., 1998). 
2.3.1 Psychodynamic Psychotherapy 
Psychodynamic psychotherapy is expressed through five core concepts: the 
influence of early-childhood experiences on current adult functioning, the power of 
unconscious functioning in human behavior, reliance on ego defenses, repetition 
compulsion, and transference (Book, 1998). Psychodynamic psychotherapy operates on 
an expressive- supportive continuum. At the expressive end of the continuum the 
primary goal is significant and substantial character change along a broad perspective. 
The primary aim of psychodynamic psychotherapy is for the patient to increase their 
understanding of internal conflict, deficits, and defensive compromises. This heightened 
understanding is expected to yield increased awareness of affects held by the patient, thus 
leading to both symptom relief as well as personality change. 
23.2 Cognitive Behavioural Therapy 
The general focus of cognitive behavioural therapy (CBT) is identification of 
dysfunctional cognitive structures that maintain unrealistic thoughts and images in 
specific situations. An underlying concept is that perception of events mediates the 
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response and ultimately determines the quality of adaptation. Treatment focuses on 
assisting patients in recognizing perceptual and cognitive errors, instructing patients to 
perceive external problems more realistically, and assisting the patient to cope with the 
more realistically perceived situations (Antony & Swinson, 1998). In essence, the 
principal aim of CBT is to change or eliminate existing maladaptive behaviors and help 
patients to acquire new adaptive behaviors, as well as, enhance current adaptive ones. 
The mechanism of change in CBT is believed to be related to changes in patients' 
thoughts and behaviors. These changes in tum lead to decreased distress as well as more 
effective interactions with others and the environment. 
2.3.3 Strategic Systems 
According to Freebury et al. (1998), strategic systems psychotherapy concerns 
itself with modification of behaviour within a given system or modification of the entire 
system. Insight is seen as antithetical to change unless it is imparted according to a 
strategic plan. Some of the strategies of this orientation are direct advice, paradoxic 
injunctions, refrarning, symptom prescription, boundary marking, and positive 
connotation. 
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2.3.4 Experiential Psychotherapy 
The primary aim in experiential psychotherapy is the sharing of feelings and 
experiences in a non-authoritarian and empathic environment (Freebury et al., 1998). The 
therapy is predominately ahistorical with the emphasis clearly focused on the "here and 
now" experience. The data source derives from both the "here and now experience" and 
the therapist's empathic awareness. Strategies of experiential therapy include abreaction 
empathy, sharing, identification, imitation, and confrontation. 
2.3.5 Eclectic Therapy 
Eclectic therapy is the label used to identify the situation in which more than one 
approach is used with a patient. Generally the therapist, and can include the patient, 
chooses an orientation which seems the most appropriate at a particular time period, but 
may also see that another orientation is more appropriate as the therapeutic relationship 
develops. Additionally, the therapist may see a particular orientation as preparation for 
another (Clarkin, Frances, & Perry, 1995). Often an orientation may present as the 
appropriate one for immediate symptom relief yet the goal is to build towards a long-term 
psychodynamic approach. Eclectic psychotherapy does not presuppose a particular theory 
of psychopathology (Hoaken and Golombeck, 1998). There is a growing consensus that 
there is no single approach that is adequate for all clients and there should be 
consideration given to matching the therapy to the client (Messer & Warren, (1 995). 
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There is mounting evidence that enhanced results may be obtained by tailoring the 
therapy to the client rather than fitting the client into the mold of one mode of therapy 
(Beutler & Consoli, 1992; Jones, Cumming, & Horowitz, 1988). Fine and Turner (1991), 
point out that the therapist with relatively ideological freedom and the motivation to 
integrate different theories enhances their potential for helping a wider spectrum of 
families. Miller, Duncan & Hubble (1997), emphasize that evidence makes it clear that 
the similarities rather than the differences between therapy modalities accounts for most 
of the change that clients experience in treatment underscoring the belief that the 
therapist need not be restricted to a specific approach but can incorporate a number of 
frameworks into treating clients. 
An excerpt from Weinberg (1995), summarizes a rationale for an eclectic 
approach to provision of psychotherapy. He states: 
"No psychotherapy is superior to any other, although all are superior to no 
treatment .... This is the conclusion drawn by authoritative reviews ... , and well-
controlled outcome studies .... This is really quite remarkable, given the claims of unique 
therapeutic properties made by advocates of the various treatments available today. " 
In addition to the definitions above, an understanding of psychotherapy can be 
gained through the general framework for most psychotherapy adapted from an article by 
Haoken and Golombek (1998). In the therapeutic process the therapist is attempting to 
provide an atmosphere in which both the patient and the therapist are demonstrably 
interested in the patient's problems and working towards change. The therapist is 
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committed to continuously showing interest in the patient's symptoms and goals as well 
as conveying hope that change is possible. The therapeutic relationship allows for 
common positive transference expectations to develop and motivate the patient (pp. 228-
229). 
2.4 Psychotherapeutic Approach Used in the Thesis RCT 
The psychotherapeutic orientation adopted in this study can be defined in terms of 
an eclectic approach. This reflects a belief on the part of the author, and indeed others, 
that patients are not only unique but may require different types of interventions at 
different times. Support for an eclectic approach is seen in the following statement 
expressed by Brouillette & Citron, (1997) " In all cases, psychotherapy should be tailored 
to the person's needs and capacities" (p. 57). There is little doubt that many different 
therapies are able to achieve goals established by both the therapist and client. However, 
it is recognized that one approach may be more appropriate than another with respect to 
the personality or situation of the individual patient. In addition it has been observed that 
a therapeutic approach might be used initially to help establish a patient therapist dyad 
while building towards a different orientation once an effective therapeutic relationship 
has been established. "The contemporary field of psychotherapy is more pluralistic: many 
diverse approaches have proven therapeutically effective and the therapist of today is 
more apt to tailor the therapy to fit the particular clinical needs of each patient" (Yalom, 
1997) (p. x). 
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Throughout the course of this trial, elements of a number of theoretical 
orientations were incorporated into the psychotherapy sessions, particularly the 
psychodynamic and cognitive/behavioural models. The interventions are best described 
as a psychodynamic orientation utilizing a range of expressive-supportive interventions 
and psychoeducation. To help understand this orientation, a brief description of these 
terms is provided in sections 2.4.1 and 2.4.2. 
To facilitate an understanding of the mechanisms of change in the psychotherapy 
sessions a list of some ofthe techniques utilized in the therapy sessions is presented. The 
techniques related to the psychodynamic orientation included: 
Expressive techniques: interpretation, confrontation, clarification, attainment of 
insight, and attention to the transference relationship; Supportive techniques: emphasis on 
the therapeutic quality of the relationship, education, counselling, modeling, reframing, 
and encouragement. 
Aspects drawn from the Cognitive Behavioral models include: role-play, 
modeling, desensitization, homework, "empty chair", relaxation exercise, cognitive 
restructuring, and graded task assignment. 
2.4.1 Psychodynamic Orientation 
All psychodynamic psychotherapies belong to what has been called the 
expressive-supportive continuum (Gabbard, 1994). Individual psychotherapy invariably 
contains both expressive (insight-oriented) and supportive elements, with one or the other 
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predominating, depending on the clinical picture at any given stage of treatment. Clinical 
interventions at both ends of the continuum contribute to good outcomes (Wallerstien, 
1986; Luborsky, 1993). When working at the expressive end of the continuum, therapists 
seek to maximize the patient's ability to self-reflect and, ultimately, achieve mature 
autonomy by helping patients to understand behaviours, thoughts, and feelings, and to 
decide for themselves how to direct them. When working at the supportive end, the 
therapist seeks to support the patient in some way compatible with mature dependence 
with the goal of helping the patient analyze their doubts and understand the longing for 
advice. 
A list of common interventions utilized at the expressive end of the continuum 
includes: interpretation, confrontation, clarification, encouragement to elaborate, and 
empathic validation. On the supportive end the therapist might include advice and praise, 
affirmation, and limit-setting. 
2.4.2. Psychoeducation 
Psychoeducation refers to the process of teaching a patient about both their 
disorder, as well as the rationale for the psychotherapy chosen. It is described by Glen 0. 
Gabbard as a model in which the nature of the patient's deficits and their implications are 
explained (Gabbard, 1994). Psychoeducation explores with the patient organic 
contributions to the patient's behaviours. An important aspect ofpsychoeducation is the 
involvement of the family, friends and care providers in the psychoeducational process. 
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Glick et al. (1994), provide the following definition: "Psychoeducation as a technique in 
clinical practice can be defined as the systematic administration by the physician of 
information about symptoms, aetiology, treatment and course, with the goals of 
increasing understanding and changing behaviour." The psychoeducation website 
www.psychoeducation.com (Psycho-Educational Counseling Services, Inc. 2002), 
provides a clear explanation as well as identifies the goals of psychoeducation 
interventions. In summary, psychoeducation involves teaching the patient, generally, and 
where possible, family members, friends, and caregivers about the disease, how to treat it, 
and how to recognize signs of relapse. Beyond just providing information related to the 
illness, psychoeducation includes teaching coping strategies, and problem solving skills. 
Recent research suggests the addition of psychoeducational interventions, for both 
patients and their families promotes compliance and leads to improved psychological 
outcomes (Glick et al, 1991). Psychoeducation has been shown to be an effective 
intervention in a variety of illnesses including depression (Dowrick eta/., 2000). 
2.5 The Therapist Effect 
In addition to the common psychotherapies, and closely associated with their 
outcomes, is one of the most critical aspects of the patient/therapist relationship. This 
aspect is the personality ofthe therapist. Extensive study of psychotherapy has 
demonstrated the personality of the therapist contributes substantially to the success or 
failure ofthe therapy (Frank & Frank 1991; Grunebaum, 1983; Strupp, 1987a). Many 
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therapists believe that the personality ofthe therapist is one of the most important aspects 
of therapy, possibly more important than any theoretical approach (Strupp, 1987b). This 
sentiment is expressed particularly well by Steven A. Caldwell, (1997), "Research 
suggests that the "real" features of the therapist- the personal qualities and interpersonal 
skills of the clinician -account for at least as much treatment outcome as specific 
techniques and theories employed. The meaningful encounter between the therapist and 
patient is facilitated primarily by the core personhood of the psychotherapist" (p. 16). 
Despite the importance of innate ability in the therapist, many people believe 
some of the attributes of a good therapist can be taught (Strupp 1978b ). In a trial to 
investigate adherence to a National Institutes of Mental Health (NIMH) manualized 
psychotherapeutic treatment procedure, Markowitz et al. (2000) showed, through 
evaluations by blinded independent raters, that therapists were adherent to the specified 
treatments after training for those treatment formats. The authors concluded it is possible 
to reliably train adherence monitors and therapists to deliver specified treatments. 
2.6 Psychotherapy in HIV I AIDS 
It is not uncommon, when treating persons living with HIV I AIDS, to hear 
frequent reports of symptoms of mood disturbances (Brouillette & Citron, 1997). Persons 
living with HIV I AIDS may experience a wide range of neuropsychiatric symptoms, 
including depressed mood, anxiety, irritability, suicidal ideation, agitation and insomnia 
(Halman, 2001). Yalom, (1997), provides a rationale for inclusion of psychotherapy in 
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the treatment of persons living with HIV. He points out a diagnosis ofHIV infection is 
likely to raise strong emotional reactions in the client, and a diagnosis of HIV infection is 
likely to raise previously unresolved concerns and even historical traumas (p. xxviii). As 
stated earlier, persons living with HIVIAIDS frequently report symptoms of mood 
disturbances. (Brouilette & Citron, 1997). Living with HIV I AIDS often means facing a 
series of crises that often overwhelm a person's usual coping ability. In addition, it has 
been shown that people with HIV who have previously experienced psychiatric 
symptoms, are more likely to experience symptoms after HIV infection (Yalom, 1997). 
An overwhelming characteristic ofHIV is its variability in terms of structure and effect 
on individuals with the virus. One of the outcomes of the variable nature of the disease 
course is a repetitive cycle of hopelessness, denial, hopelessness, as patients experience 
changes from physical and psychological good health to poor health and back again 
(Ostrow, 1997). As David G. Ostrow points out, and this is observed by many providers 
of psychotherapeutic interventions to persons living with HIV and AIDS, "Thus there is 
an inherent affective instability that comes with HIV infection and with attempts to gain 
control over its seemingly inevitable encroachment .. . "(p. 34). 
Patients living with HIV incur multiple losses, which include health, autonomy, 
social networks, mental acuity and economic security. A routine observation in the 
management of HIV treatment is that losses are not paced and many of the losses can 
happen concurrently or in very rapid succession contributing to decreased psychological 
well being (Ostrow, 1999). Another observation in the management of persons living 
with HIV I AIDS (PWHA) is an increase in feelings of demoralization (Treisman, 
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Angelino, & Hutton, 2001). Demoralization, which is an exaggerated grief state in which 
the patient has a pervasive sense of sadness, low mood, or hopelessness that interferes 
with usual activities, is different than depression in that it is not a brain disease and is 
more likely to respond to psychotherapy than antidepressant medication. 
Depressed mood is the most common neuropsychiatric complaint in persons with 
HIV/AIDS seeking psychiatric evaluation (Halman, 2001). Earlier studies, using self 
reported measures of depression, found a point prevalence of 20 % to 30 % while studies 
using standardized interviews found point prevalence of 4 % to 18 % Brouillette & 
Citron, 1997). According to Perry (1994), low-grade depressive symptoms are frequent in 
HIV positive individuals and depressive disorders occur in about one in ten. 
This variation in estimates of the prevalence of depression in HIV can be 
explained by several factors. The diagnostic criteria for major depression are felt to lose 
their specificity in medically ill populations. The variability in the population samples, 
the variability in the interval defined as point prevalence (1-6 months) and variability in 
the instruments used to assess psychopathology contribute to the variation in estimates. 
Also contributing to point prevalence variation is the influence of comorbidity with other 
psychiatric diagnoses. 
Initially, it was felt that depression rates were about the same in HIV positive 
patients as in the general population, though most of the estimates were based on weak 
information sources. It is generally accepted that rates for major depression in persons 
living with HIV are higher than in the general population. More recent studies indicate 
the prevalence rate of major depression in persons with HIV I AIDS is more likely to be 22 
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%to 45% (Halman, 2001). Treisman eta/. (2001), estimate about 60% ofHIV-
infected patients have a depressive episode sometime in their illness. Despite differences 
in opinion related to prevalence and incidence, there is substantive agreement amongst 
professionals that psychotherapy in an integral part of the treatment of depression in 
people living with HIV (Brouilette & Citron, 1997). 
2. 7 Defining Depression 
Depression is generally abstracted into "major depressive episode" and recurrent 
depressive disorder. Depression is viewed as a disease with a number of what are thought 
of as "core" symptoms. These symptoms include, a lowering of mood to a degree that 
would be viewed as abnormal for the particular individual experiencing the mood, loss or 
reduction in energy, and a loss of interest in, or decrease in enjoyment of, normally 
pleasurable activities. 
To meet International Statistical Classification ofDiseases and Related Health 
Problems, Tenth Edition (ICD-10) criteria for depression, at least two of these core 
symptoms must be present for at least two weeks. Additional symptoms from the 
following list can be used to affirm a diagnosis of depression. The list includes: loss of 
confidence, feelings of guilt, thoughts of suicide, poor concentration, changed sleep, 
changed appetite, and agitation or retardation. 
To aid in an understanding of the severity of depression, mild depression is 
thought to be present when a total of four symptoms from the two lists are present. For a 
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diagnosis of moderate depression, at least six symptoms from the two lists should be 
present. When eight symptoms are present, and includes all three of the core symptoms, 
the patient is thought of as having a severe depressive episode. 
To meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition (DSM-IV) criteria for a Major Depressive episode the patient must experience the 
presence of five or more symptoms, in the same 2-week period, from a list which 
includes depressed mood, anhedonia, altered sleep, altered appetite, altered weight, 
fatigue, psychomotor agitation or retardation, diminished concentration, guilt and 
suicidality. Additionally at least one of the symptoms must be either depressed mood or 
anhedonia (absence of pleasure from acts that would ordinarily be pleasurable) and the 
symptoms cannot be directly explained by general medical condition. 
Other depression syndromes include the following: 
• Dysthymia, which is chronic and prolonged depressed mood which continues for 
more than 2 years but does not usually satisfy the criteria for a depressive episode. 
• Bipolar Depression, which is characterized by the occurrence of one or more 
major depressive episodes accompanied by at least one Hypomanic Episode. 
• Cyclothymia, which may be thought of as chronic mood swings. 
• Adjustment Disorder with Depressed Mood, which is depressed mood, not 
meeting criteria for a major depression, occurring within two months of definable 
stressor and remitting within six months of cessation of the stressor. 
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• Bereavement, characterized by depressed mood after the death of a loved one, 
which is allowed to meet the criteria for major depression for the first two 
months. 
• Depression Secondary to Psychiatric or General Medical Disorders or to 
Psychoactive Substances, where the depressive symptoms are secondary to other 
medical conditions or drugs. 
• Depression NOS, which is simply depressed mood which does not meet the 
criteria for any of the above syndromes. 
For more detailed information on these conditions please refer to the American 
Psychiatric Association (1994), Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition, or any professional manual on mental disorders. 
Recurrent depressive disorder is established as the diagnosis when the patient 
experiences two or more episodes of depression. 
Rosenbaum (1996) goes beyond the definitions to more clearly express what 
patients report when they are depressed: 
"Perhaps we should have a different name for the syndrome that drains the zest 
for living and replaces it with anguish, guilt, pessimism, irritability, and the 
inability to experience pleasure - a condition that saps the appetite for food as 
well as for life, blocks access to the sanctuary of sleep, depletes energy and the 
motivation to rally, and fills the mind with morbid thoughts, including the wish to 
be dead." (p. 1). 
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So often, descriptions similar to this, are heard from patients experiencing depression and 
frequently the words are accompanied by tears and trembling. This, more than an ICD-1 0 
or DSM-IV description, is the face of depression. 
2.8 Prevalence and Incidence of Depression 
Since so many of us have encountered someone who has experienced depression, 
it should come as no surprise that it is one of the most common psychiatric illnesses 
(Canadian Mental Health Association, 1995). It is estimated that between 2.3% and 3.2 
%of men and 4.5% to 9.3% of women in western countries suffer from major 
depressive disorder (U.S. Department ofHealth and Human Services, 1993). Ifthe minor 
forms are added to the major depressive episodes category then it is more likely that 10 % 
of the population suffers from depression (Cassem and Coyle, 2002). A study by Murphy 
(1990) indicated that 5% of the Canadian population suffers from depression at any one 
time. 
The overall lifetime prevalence estimates of clinically significant depression 
range from 15% to 30% (Canadian Task Force on the Periodic Health examination, 
1990). The point prevalence of depression in the general population has been reported 
from a low of3.5% to a high of27% (Canadian Task Force on the Periodic Health 
examination, 1990). This wide variation is associated with variability in the populations 
under study, variability due to the assessment tools used, as well as variability of 
definitions of depression. Reporting depression prevalence information is generally 
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derived from a diagnostic interview or self-report questionnaires (Canadian Mental 
Health Association, 1995), and there appears to be higher percentages of depression from 
self-reported questionnaires (Brouillette & Citron 1997. This may also contribute to the 
variability in estimates. Even if someone chooses to accept only the lower end of the 
estimates, there are undoubtedly many millions of people who have experienced, are 
currently experiencing, or can expect to experience depression. 
2.9 Depression in HIV I AIDS 
Depression is a major factor associated with decreased quality oflife in patients 
with HIV/AIDS, and major depression is a primary risk factor for suicide in the HIV 
population, as well as the general population (Fawcett eta/., 1990; Rundell et a/., 1992). 
Major depression has been associated with decreased survival in persons living with HIV 
disease (Mayne eta/., 1996) as well as decreased immunological function (Evans et al., 
1997). 
In summary there appears to be clear evidence of a role for psychotherapy in the 
management ofHIV disease. S.W. Perry (1994), reports that accumulated clinical 
experience and a couple of systematic studies suggest that psychotherapy alone or in 
combination with antidepressant drug therapy can be remarkably beneficial in treating 
HIV-infected patients. "Given the nature of this illness and the stresses associated with it, 
psychotherapy should be an integral part of psychiatric care for someone living with 
HIV." (Brouillette & Citron, 1997) (p. 57). 
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Clearly, the addition of a diagnosis of HIV brings about new psychological issues 
and exacerbates previous and existing conditions. Depression is a condition strongly 
associated with living with HIV and AIDS. It seems reasonable to conclude there is a 
role for psychotherapy in the management of HIV disease. 
2.10 Evaluation of the Major Clinical Trials Related to the Primary 
Outcome Measure of the Thesis RCT 
In order to portray an understanding of the role of psychotherapy in the 
management of HIV disease at the time this trial was undertaken, this section will review 
the literature up to the period 1996 when the clinical trial, which is the subject of this 
thesis, was begun. Trials investigating the impact of psychotherapy on HIV and AIDS 
which were published after the start of this clinical trial, as well as studies directly related 
to secondary outcome measures, will be presented in the discussion chapter of this 
document. 
The focus of the discussions of the research related to psychotherapy and 
HIV I AIDS will be concerned with Randomized Controlled Trials. There is non-
experimental evidence to support the possibility ofbenefit due to psychotherapy, but in 
the presence of experimental evidence from RCTs this researcher chose to limit 
discussion, generally, to results obtained from this stronger evidence source. 
There is an abundance of literature describing psychological issues that confront 
persons diagnosed with HIV/AIDS. These include: depression, hopelessness, chronic 
somatic preoccupation, fear of development of illness, debilitation, anger, frustration, 
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societal ostracism and anxiety (Mulder et al., 1994; Kelly et al., 1993; Perry et al., 1991). 
Throughout the course of the disease, episodic feelings of depression and hopelessness, a 
decrease in self-esteem, decreased coping skills, and lower ratings of quality of life may 
be present. The available literature suggests these outcomes are persistent and a role for 
psychotherapy is strongly indicated as an integral component ofHIV management 
(Lutgendorf et al., 1994). 
There is consensus that a need exists for controlled outcome studies that assess 
the effects of psychotherapeutic interventions on depression relief in persons living with 
HIV (Markowitz et al, 1995). In their 1995 article Markowitz et al. claim that their trial 
was the first controlled study of individual psychotherapies for depressed HIV positive 
patients. This assertion is supported by an extensive literature search undertaken as part 
ofthis study. 
An initial observational study of23 adults with HIV infection, by Markowitz et 
al., 1992, demonstrated a decrease in depression scores in HIV positive patients who met 
DSM-III- R criteria for nonpsychotic major depression or dysthymia enrolled in an 
interpersonal psychotherapy (IPT) program lasting 16 sessions. The authors suggest 
mental health workers should consider IPT as a treatment for depressed HIV positive 
patients. 
There are a number of weaknesses associated with this study. There was no 
control group, allowing for conclusions that improvements may be explained by factors 
other than the psychotherapeutic intervention. Time alone could have accounted for the 
improvement seen in the study subjects. In addition, the sample size was quite small. 
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Although depression was resolved in 87 % of cases, it was not measured in the 
same way for all23 subjects. Five subjects were assessed with the Hamilton Depression 
Rating Scale (HRSD), whereas 18 were evaluated by therapists' global clinical 
impressions and patients' subjective assessment. Using different outcome measures for 
different subjects brings into the question the credibility of the study findings. Two 
different therapists treated the study subjects and there is no mention of any analysis 
looking at therapist effects. 
All but two subjects were physically asymptomatic, limiting information related 
to the effects ofiPT on symptomatic subjects. Additionally, conclusions cannot be drawn 
regarding a role for psychotherapy for non-depressed patients living with HIV/AIDS. 
Finally, the authors provide no follow-up information regarding the patients, 
consequently, nothing can be concluded about the lasting effects ofiPT on depression in 
adults living with HIV. 
A later randomized controlled trial by Markowitz eta/. (1995), of32 gay or 
bisexual male subjects, showed improved depression scores in HIV -positive patients 
receiving 16- week interventions of interpersonal psychotherapy or supportive 
psychotherapy. In addition, the authors observed a potential advantage of interpersonal 
psychotherapy over supportive therapy. 
The subjects in this trial were randomized to either interpersonal psychotherapy 
or supportive psychotherapy. Analysis of baseline characteristics indicated the groups 
were similar. 
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The design of this RCT provides limited credibility to the authors' conclusion that 
both these psychotherapies can lead to a decrease in depression scores in subjects with 
HIV disease. One of the major problems with this study is the absence of a control group, 
thus many factors, other than the psychotherapy, could have accounted for the 
improvement in the study subjects. Simple passage of time, or enrollment in a trial, or 
psychological testing, etc. could explain changes, and a control group would have helped 
address concerns such as these. 
Another problem is the homogeneity of the subjects. All subjects were gay or 
bisexual, asymptomatic and all were males. This limits the generalizabilty of the effects 
of these two psychotherapies to a heterosexual population, symptomatic population and 
to females. 
All subjects in this trial had a Hamilton Depression Rating Scale score of at least 
15 and clinical impression of a DSM-III-R mood disorder. This does not allow for any 
conclusions regarding the effects of psychotherapy in a HIV population heterogeneous 
with regards to levels of depression. 
In addition, there was no patient follow-up, limiting any conclusion regarding the 
ability of the short-term interventions to maintain a depression free state. The authors also 
point out that they used a relatively small sample size. 
Target al. (1994), examined the effects of a 12-week treatment interval of 
structured group therapy and fluoxetine compared to structured group therapy and 
placebo in 20 depressed homosexual subjects who met the criterion for major depression 
or adjustment disorder with depressed mood. Patient demographics were similar at 
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baseline and subjects were randomized to receive either fluoxetine or placebo and blinded 
to medications. Subjects were assessed using the Hamilton Depression Scale (HAM-D) 
and the Profile of Mood States (POMS). Although both groups demonstrated a significant 
improvement in several measures of depression and anxiety, there were no significant 
differences on psychological measures between the groups. The authors concluded that 
by using structured group therapy depressive symptoms can be relieved without a 
pharmacological intervention. 
It is possible, in the absence of a control group, that patients just improved on 
their own. None of the 20 patients were symptomatic and were included only if they had 
no concurrent drug or alcohol abuse. This limits conclusions regarding the effectiveness 
of structured group therapy on symptomatic patients and patients who might have alcohol 
or drug related problems. 
The homogeneity of the trial subjects limits the generalizabilty of the conclusions. 
The absence of any females or heterosexual subjects could provide support for an 
argument that the findings only apply to gay males. 
Typically there was no mention of follow-up, which could assess the ability of the 
intervention to maintain absence of depression. The authors also report no differences 
between groups on CD4+ and CD3+ cell counts. 
Mulder eta!. (1994) investigated the effectiveness of 15-week cognitive 
behavioral group psychotherapy (CB) and an experiential group psychotherapy (ET) 
program for 39 HIV -positive homosexual men. Patients were administered the BDI, the 
General Heath Questionnaire (GHQ) and a Dutch versions of the POMS. Their findings 
57 
suggest that psychosocial interventions significantly decreased distress compared to a 
wait list control group. In addition they found no benefit of one therapy over another, 
suggesting patients should be allowed to choose their preferred therapy. 
Support for the authors' conclusions is strengthened by the fact that patients in 
this study were randomized to the three experimental conditions: cognitive-behavioral 
group therapy (CBGT), experiential group therapy (EGT), or a waiting-list control. In 
addition, the authors state the three groups had similar demographics at baseline. 
This study is typical in that the subjects are homosexual males thus limiting 
generalizations to heterosexuals and females. There was no investigation of any long-
term effects of the psychotherapy. All subjects were asymptomatic and had no history of 
drug or alcohol dependency. This restricts any conclusions related to the success of these 
interventions for symptomatic patients or patients with drug or alcohol use. In recognition 
of the fact that alcohol and drug related issues often accompany HIV infection, the study 
could have been improved by including subjects with these issues. 
Kelly eta/. (1993) compared the outcomes of an eight-session cognitive-
behavioural group, eight-session social support group and a comparison group (only 
administered assessment measures) in 68 depressed predominately homosexual males 
with HIV infection. Psychological measures were obtained using the Center for 
Epidemiologic Studies Depression scale (CES-D), the Social Provisions Scale (SPS), the 
Symptom Checklist 90- Revised (SCL-90-R), and the Multidimensional Health Locus of 
Control Scale (MHLCS). Both interventions reduced depression, hostility, and 
somatization compared to the control group. 
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Aspects of this trial, such as randomization of subjects to treatment and control 
conditions, inclusion of symptomatic as well as asymptomatic patients, and patients with 
history of alcohol and drug use, enhance the generalizabilty of the finding of benefit due 
to the provision of psychotherapy. 
Although 10 females entered the study, they wished to attend only groups with 
other females and thus were dropped from the analysis, leaving only an analysis 
conducted on the male patients. It is arguable that data for these women should have been 
included in the analysis or at least a separate analysis containing both males and females 
should have been conducted. Again, this limits conclusions that can be drawn regarding 
the benefits of group psychotherapy for females. A total of 115 subjects were recruited 
but only 68 had complete follow-up and were included in the analysis. The authors stated 
that most of the losses were attributable to severe illness. Clearly, the authors' conclusion 
underrepresented the patients with greater disease severity. It is generally expected that 
all patients be included in the analysis particularly if there might be a strong association 
with the primary outcome. The loss of almost 41 %of trial subjects presents a strong 
challenge to the confidence in the authors' conclusions. As in the preceding trials, only 
subjects with probable depression entered the study so little can be said about the effects 
of psychotherapy in nondepressed individuals. 
There was a three-month follow-up but only the social support group continued to 
differ significantly from the comparison subjects. This indicates a need to compare the 
effects of short versus long-term effectiveness in managing depression in HIV disease. 
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Over 94 % of subjects were homosexual or bisexual limiting conclusions 
regarding the effects of these two therapies in heterosexual patients. 
2.11 Secondary Outcome Measures 
In addition to examining the role of psychotherapy in the treatment of depression 
in persons living with HIV, secondary issues such as the effects of psychotherapy on 
hopelessness, coping, and CD4 T lymphocyte cell counts were considered in this study. 
Though these issues were not of primary interest, they are strongly correlated with 
psychological well-being and are important considerations in the management ofHIV 
and AIDS. 
2.11.1 Hopelessness 
Hopelessness is a psychological construct that has been observed to underlie a 
variety of mental disorders. It is conceptualized as a system of cognitive schemas in 
which the common denominator is negative expectancy about the short and long term 
future (Beck & Steer, 1993). Several beliefs are observed in individuals described as 
hopeless. Hopeless individuals believe nothing will tum out right for them, they will 
never succeed at what they attempt to do, important goals can never be obtained, and 
their worst problems will never be solved. The North American Nursing Diagnosis 
Association (NANDA) describes hopelessness as a subjective state in which an 
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individual sees limited or no alternatives or personal choices available and is unable to 
mobilize energy on own behalf(Fortinash & Holoday-Worret, 2000). Some defining 
characteristics of persons diagnosed as suffering with hopelessness include verbalizations 
that life, situation, or status seem hopeless or futile, frequent sighing, decreased or absent 
verbalizations, decreased affect, withdrawal, decreased appetite, increased sleep, lack of 
involvement in care, lack of interest in significant others. 
Hopelessness was assessed in this study because of its' strong association with 
depression and suicide. In addition to the preceding associations, the clinical team 
treating HIV/AIDS observed repeated complaints ofintense feelings ofhopelessness 
amongst the HIV positive patients. As well, reports of feelings of hopelessness are 
frequently reported in the IDV I AIDS literature. This researcher felt that interventions, 
which might decrease hopelessness, would likely improve quality of life. 
2.11.2 Coping 
Coping has primarily been conceptualized as a response to external stressful or 
negative events (Endler & Parker, 1990a). The person's responses to the events usually 
involve conscious strategies. A more precise definition is provided by Folkman (1984) 
"Coping refers to cognitive and behavioral efforts to master, reduce, or tolerate the 
internal and/or external demands that are created by the stressful transaction." 
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Different theoretical orientations affect how coping is defined. Coping is 
sometimes viewed as a stimulus response relationship, or a product of intrapsychic 
conflict centering on the persons needs, motives, impulses, or beliefs. Despite differing 
orientations, most people agree that there is not a simple relationship between stress and 
coping, that believing an event is controllable does not always lead to reduction in stress 
and believing that an event is uncontrollable does not always lead to an increase in stress 
(Thompson, 1981). It has become clear that there is an important relationship between 
the impact of a stressful event, the coping mechanisms applied and the significance or 
meaning of the event to the individual experiencing it. 
For the purpose of this study, and because it is an underlying assumption of the 
Coping inventory for Stressful Situations (CISS) used in this study, coping is viewed as 
having 2 major functions: the regulation of emotions or distress (emotion-focused 
coping) and the management of the problem that is causing the distress (problem-focused 
coping). 
One of the reasons to measure coping in this patient population is that emotion-
oriented and avoidance-oriented coping have been associated with psychopathology, and 
task-oriented coping has been found to be negatively related to low self esteem, cynicism, 
depression, and anxiety (Endler & Parker 1990a). Many investigators have observed 
that psychologically ill persons are prone to use emotion-oriented coping and avoidance-
oriented coping strategies more frequently or in preference to task oriented coping 
strategies, whereas psychologically well persons are prone to using task-oriented coping 
in preference to other coping strategies. 
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2.11.3 CD4 T-lymphocytes and Viral load 
CD4 cell counts were measured in this trial for two main reasons. When this trial 
began CD4 T -cell counts were utilized as a measure of disease severity and treatment 
effectiveness. Perhaps more important, is the role patients have given to CD4 cells as a 
marker of their health status. Patients viewed their number of CD4 cells as a strong 
indication of their disease severity and prognosis. 
2.12 Summary 
In conclusion, at least up to 1996, the evidence from clinical trials investigating 
the benefits of psychotherapy in treating depression in persons living with HIV/AIDS 
was limited. Few studies existed and some have methodological concerns. The studies 
investigated short-term provision of psychotherapy and generally its impact on 
homosexual males. In 1996 there was definitely a need to examine a role for long-term 
psychotherapy, the effects on heterosexuals living with HIV, the impact on HIV positive 
females, and the impact independent of severity of disease. The RCT discussed in this 
thesis was intended to help address some of these issues. 
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CHAPTER3 
MATERIALS and METHODS 
3.1 Depression Measured in the Thesis Clinical Trial 
The revised Beck Depression Inventory (BDI) was utilized to assess depression in 
the research subjects (Beck & Steer 1993). The revised BDI, developed form the original 
BDI, by Becket al. (1961), is a 21-item inventory frequently used to assess somatic, 
affective, behavioral and cognitive aspects of depression. 
Reliability estimates based on Cronbach's coefficient alpha for mixed, single-
episode major depression, recurrent-episode major depression, dysthymic, alcoholic, 
heroin-addicted patients, and nonpsychiatric samples are .86, .80, .86, . 79, .90, .88, and 
.81 respectively. 
The BDI has been shown to be able to discriminate between Dysthymic and 
Major Depressive Disorders as well as differentiate between Generalized Anxiety 
Disorders and Major Depressive Disorders. The revised BDI has also been shown to be 
able to differentiate among psychiatric, medical and normal samples. 
Numerous studies ofthe construct validity of the BDI have been conducted with 
different variables and significant correlations have been observed between constructs 
hypothesized to be associated with depression (Beck et al. , 1988). 
A Meta-analysis found a mean Pearson product-moment correlation of. 72 
between clinical ratings of depression and BDI in psychiatric patients and .60 between 
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clinical ratings of depression and BDI in nonpsychiatric subjects. In addition, significant 
correlations with other standardized depression measures have been reported for the BDl. 
Shafer et al. (1985) reported significant correlations between the BDI, Depression Scale 
of the Minnesota Multiphasic Personality Inventory (MMPI-D Scale), and Zung Self-
rating Depression scale with all correlations exceeding .55. BDI has also been correlated 
with the (Symptom Checklist -90- Revised (SLC-90-R) Depression-Dejection Scale (.76) 
(Derogatis, 1977). Of particular relevance is the significant correlation (.73) between BDI 
and the Hamilton Psychiatric Rating Scale for Depression (HRSD). These two scales are 
amongst the most popular scales used to assess depression and are often used together for 
evaluating self-reported and clinically observed changes in depression. One advantage of 
the BDI over HRSD is that it is less likely to overestimate improvement in patients 
receiving drug therapy or psychotherapy (Edwards et al. 1984; Lambert et al. 1986). 
BDI is listed by the Canadian Mental Health Association (CMHA) as one of the 
commonly used scales for measuring depression. (Canadian Mental Health Association, 
1995). Others listed by the CMHA are: Zung Self-Assessment Depression Scale, 
Hamilton Rating Scale, Hopkins Symptom Checklist; Center for Epidemiological Studies 
Depression Scale, General Health Questionnaire, MacMillan's Health Opinion Survey, 
Lagner's Scale, Schedule for Affective Disorders and Schizophrenia, Diagnostic 
Interview Schedule Self-Administered, Structured Clinical Interview for DSM -111-R, 
Bradburn Affect Balance Scale. 
The BDI was chosen for this study for a variety of reasons, which include: 
• Its extensive use as a tool to assess depression. 
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• It has been validated in a psychiatric and non-psychiatric populations. 
• Its familiarity amongst professionals and paraprofessionals. 
• It has been in use since 1961. 
• Improvements in the revised edition were developed in 1971. 
• Its recognition as a standardized assessment tool by the CMHA. 
• Its past use in trials investigating the impact of psychotherapy in HIV disease. 
• The revised BDI scores are not meaningfully related to gender and age. 
• Its ease of administration. 
There is considerable overlap between the standardized depression questionnaires, and 
this researcher is unaware of any valid arguments against the use of the BDI to assess 
depression in patients with HIV infection. 
To aid in understanding the scoring of the BDI the following information is 
beneficial. The maximum possible score is 63 and increasing scores are indicative of 
increasing levels of depression. A score of 0-9 is considered to be minimal, 10-16, mild, 
17-29 moderate, and 30-63 severe depression (Beck, 1993). In arriving at a diagnosis of 
depression, scores greater than 15 are considered indicative of depression (Beck & Steer, 
1993). In conjunction with a BDI above 15, an interview by a trained professional is 
recommended to confirm presence or absence of depression. 
One of the unique features of this trial is that HIV I AIDS patients were included 
unrelated to presence or absence of symptoms of depression. The depression assessment 
tool was used to measure individuals after enrolment in the trial. 
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3.2 Hopelessness Measured in the Thesis Clinical Trial 
In this clinical trial, the 20-item BECK Hopelessness Scale (BHS) was used to 
assess patient feelings ofhopelessness. The BHS maintains high internal consistency 
across clinical samples. The Kuder-Richardson (K.R-20) reliabilities for suicide ideators, 
suicide attempters, alcoholics, heroin addicts, single-episode Major Depression 
Disorders, recurrent-episode Major Depressive Disorders, Dysthymic Disorders (Beck & 
Steer, 1993) were, .92, .93, .91, .82, .92, .92, .87 respectively. Durham (1982) reported 
lower correlations in college students (K.R-20 = .65). 
Test-retest measures of patients with mixed diagnoses yielded Pearson product-
moment correlations after 1 week of .69 and six weeks of .66. 
Face validity was established through a review process using several clinicians. 
Correlations with clinical ratings of hopelessness were .74. The BHS has been 
shown to be able to differentiate DSM-III Major Affective Disorders (Major Depression, 
Dysthymic, etc.) from Generalized Anxiety Disorder (GAD). 
The BHS is a standardized measure of hopelessness, and like depression can 
categorize hopelessness as minimal, mild, moderate, and severe (Beck, 1993). The 
maximum possible score is 20 and increasing scores are indicative of increasing levels of 
hopelessness. A score in the range of0- 3 is considered minimal, 4-8 mild, 9-14 
moderate, and greater than 14 severe. Beck (1986) reported that hopelessness has 
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repeatedly been found to be better predictor of suicidal intention than depression. This 
finding has been supported by Wetzel (1976) and Dyer and Kreitman (1984). 
3.3 Coping Measured in the Thesis Clinical Trial 
Coping skills were assessed with the Coping Inventory for Stressful Situations 
(CISS) (Endler & Parker, 1990). An underlying assumption of the CISS is that coping has 
two major functions: the regulation of emotions or distress (emotion-focused coping) and 
the management of the problem that is causing the distress (problem-focused coping). 
Endler & Parker (1990a) report the alpha coefficients, measuring internal 
consistency are highly satisfactory across normative groups, though slightly lower, but 
still highly reliable for psychiatric patients. 
Test-retest reliabilities conducted over a six-week period were in the moderate to 
high range. A similar pattern was seen in mean inter-item correlations indicating internal 
stability of the scale. 
Factor analysis produced three main scales, task-oriented coping, emotion-
oriented coping and avoidance-oriented coping. Congruence coefficients above .95 
support a conclusion that the factor structure for psychiatric samples and nonpsychiatric 
samples are the same. 
Construct validity was established through comparisons with the Marlowe-
Crowne Social Desirability Scale (M-C) and correlation indicated the CISS is not 
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influenced by social desirability. Additional comparisons with the Ways of Coping 
Questionnaire (WCQ), Basic Personality Inventory (BPI), MMPI-2, BDI, etc. provide 
support for the construct validity of the CISS, and support the belief that it is a 
multidimensional instrument that independently assesses task-oriented coping, emotion-
oriented coping, and avoidance-oriented coping in psychiatric and nonpsychiatric 
populations. 
The CISS assessment tool consists of 48 items used to assess task-oriented 
coping, emotion-oriented coping and avoidance-oriented coping. A voidance-oriented 
coping has two subscales: distraction and social diversion. The higher the test score on 
any one of the five subscales the greater the degree of coping activity for the person on 
the corresponding coping dimension. A maximum score of 80 can be obtained on each of 
the three main scales, task, emotion and avoidance. The maximum score on the avoidance 
subscale distraction is 40 and social diversion 25. 
3.4 CD4 T -lymphocytes Measured in the Thesis Clinical Trial 
Morning peripheral venous blood samples were collected in ethylenediamine 
tetraacitic acid (EDT A) tubes from all participants. Lymphocyte counts were determined 
by whole blood direct immunofluorescence flow cytometry. Comparisons were made 
utilizing normal rages (700-1100 cells/mm3), established by Hannett et al., (1992). No 
additional blood samples were required for this study as routine blood sample analysis 
was an aspect of standard of care. 
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3.5 Subjects 
The study population consisted of 31 HIV positive adults receiving treatment at 
the Infectious Diseases Clinic of the Health Care Corporation of St. John's, 
Newfoundland and Labrador, Canada. Cognitive impairment was the sole exclusion 
criterion. The Human Investigation Committee (HIC) of Memorial University of 
Newfoundland and Labrador granted ethics approval for this study. Ultimately, the study 
sample represented approximately half of the HIV population served by the tertiary 
referral centre. 
Potential subjects were approached by one of the 2 HIV clinical team physician 
specialists or by the HIV nurse coordinator. After the study was explained to the patient, 
signed consent, using a form previously approved by HIC, was obtained. 
The sample size calculation was based on a standard deviation of the six-month 
change in BDI of 8 and was powered to detect a change of 10 units over six months with 
a power of 80 % and an assumed drop out rate of 20 %. 
3.6 Therapist 
The therapist in this trial, who was also the principal investigator of the RCT and 
author of this thesis, has both university training as well as extensive participation in 
continuing professional training in psychotherapy practice. In addition, the therapist has 
received training specifically related to provision of psychotherapy to persons living with 
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HIV I AIDS. He has been employed as a therapist in institutional settings, residential 
counselling and psychotherapy programs, and private practice for over twenty years. 
Additionally the therapist has been involved in supervision of senior social work student 
field placements. 
3.6.1 Randomization and Stratification 
Patients were randomized to one of two groups, psychotherapy (treatment group) 
or crisis intervention (control group). Balanced block randomization was used, using 
variable block size of2, 4, and 6 subjects. A single individual, who was not involved in 
either the care of the patients, or the study itself, performed the randomization. To 
address concerns that group availability might influence the order in which patients were 
recruited by the clinical team, blinding to next group availability was strictly adhered to. 
Neither the HIV clinical team, patients or research therapist had knowledge of which 
group successive patients would be assigned. 
Patients were stratified according to the severity of their baseline CD4 count; CD4 
< 200 or CD4 :2: 200. 
Prior to randomization, the therapist administered the standardized psychological 
tests. These were repeated at six and twelve months. Test scores were not calculated 
until the last subject had completed the trial. 
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3.6.2 Intervention 
Patients (N=l7) enrolled in the psychotherapy group received routine 
psychotherapy sessions at a frequency determined by collaboration between the patient 
and therapist. An eclectic model was used, however the primary orientation was a 
psychodynamic one utilizing a range of expressive-supportive interventions and 
psychoeducation. Interventions were given to all patients in person and by telephone. In 
addition to the above modes of contact, patients who wished to communicate by e-mail 
had this format incorporated into their interventions. Therapy sessions were scheduled 
weekly for the first six months of the trial and bi-weekly for the last six months of the 
trial. In person therapy sessions were approximately 50 minutes duration. The study 
therapist was available by hospital pager and hospital operator on a 24-hour call basis for 
the duration of the trial to provide crisis intervention when required. 
Patients (N=14) enrolled in the crisis intervention (control) group were provided 
psychotherapy by the study therapist when it was deemed necessary by the HIV treatment 
team, and timely access of a psychotherapeutic intervention was unavailable outside the 
study setting. In addition, control group patients could access psychotherapy services 
through their primary care physician. 
There were challenges to maintaining a control group which could be 
conceptualized as a "crisis intervention only model" or "current standard of care" model. 
These concerns focused on whether it was ethical to withhold therapy to a control patient 
when the HIV clinical team felt an intervention was warranted. Rationalizing that 
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patients were involved in a RCT and that the control patients still received standard care 
was felt inadequate by members of the clinical team; hence some control patients were 
treated by the study therapist when the normal channels could not provide a timely 
intervention. Thus, in the strictest sense, the control group was not the usual standard of 
care. Every effort was made to minimize study therapist interventions but such 
interventions did occur. The most likely effect of these interventions would have been to 
decrease the likelihood of significant differences between the treatment and control 
groups. In effect, the significant differences observed between the two groups was, 
perhaps, even stronger since both groups were receiving enhanced psychological care. 
3.6.3 Outcome Measurements 
The objective ofthis study was to compare continuous psychotherapy (the 
intervention group) to no psychotherapy, except for the purpose of crisis intervention (the 
control group). The primary outcome measure was the six-month depression score on the 
BDl. The secondary outcome measures were the 12-month depression score on BDI, the 
6 and 12-month hopelessness scores on the BHS, the 6 and 12- month coping skills score 
on CISS and 6 and 12-month CD4 cell counts. 
The primary outcome was evaluated using analysis of covariance (AN COY A) 
with the six-month depression score as the dependent variable, baseline depression score 
and stratification as covariates, and treatment assignment as the comparison variable. The 
secondary outcome, six and 12-month comparisons were handled similarly. In addition, 
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the primary and secondary outcome measures were evaluated without stratification as a 
covariate in the model. 
An analysis was also conducted adjusting for gender, age, marital status 
(described as living with partner in table 4.1), route oftransmission and sexual 
orientation to assess their influence on the primary and secondary outcomes. 
The analyses presented in detail in this report did not include dropouts or patients 
who remained in the trial but who were unavailable at the time of the scheduled 
psychological testing intervals. All analyses were also performed using the a priori 
scenario of carrying forward the last existing value for missing values. 
3.6.4 Selected Issues Explored in Psychotherapy 
A wide variety of issues were explored during therapy sessions. There were issues 
specific to individual patients, such as childhood sexual abuse and common issues such 
as decline in CD4 T -cell counts and changes in weight. Sessions explored, but were not 
limited to, feelings of depression, feelings of hopelessness, suicide ideation, physical and 
sexual abuse, low self esteem, loneliness, fear of pain, fear of abandonment, death, family 
dynamics, previous sexual history, prescription and non-prescription drug usage, loss of 
autonomy, loss of ability to procreate, employment, initiation and/or change of 
antiretroviral therapy, etc. 
Primarily, crisis intervention occurred around suicide ideation and/or suicide 
attempts. Patients often sought an intervention, outside scheduled therapy sessions, when 
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they described themselves as "feeling totally hopeless" and "having no reason to live" 
and " happier if they were dead". Notification to patients of significant decline in CD4 
cell counts was often a precursor to requests for therapy outside the scheduled sessions. 
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4.1 Patient Demographics 
CHAPTER4 
RESULTS 
Between March 1996 and September 1997,31 subjects were enrolled in the study. 
The subjects had a mean age of 30 years, mean depression score of 22, mean 
hopelessness score of 10, mean coping inventory for stressful situations task score of 52, 
emotion score 51, avoidance score 47, distraction score 24, social diversion, 15 and mean 
CD4 count of277 cells/J.ll. A total of 48.4% of patients had CD4 counts< 200 cells/J.ll. 
The baseline characteristics of control and intervention patients are shown in 
Table 4.1. Control group subjects (N=14) were 93% male (N=l3), had a mean age of33 
years, a mean weight of74.9 kilograms, and mean CD4 T-cell counts of332.57 cells/f..ll. 
Twenty-one percent (N=3) of control subjects were living with a partner, and 71% 
(N=lO) were ofhomosexual orientation. Thirty-six percent (N=5) were not taking HIV 
medications, 50% {N=7) were taking two HIV medications, and 14% {N=2) were 
prescribed triple therapy. Infection was attributed to heterosexual activity in 21 % of the 
control subjects (N=3), homosexual activity in 71% (N=lO), blood products in 7% (N=l) 
and IV drug use in 0%. 
Treatment group subjects (N=17) were 65% male (N=ll), had a mean age of 28 
years, a mean weight of69.36 kilograms, and mean CD4 T-cell counts of231.82 cells/J.ll. 
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Thirty-five percent (N=6) of treatment subjects were living with a partner, and 59% 
(N=10) were ofhomosexual orientation. Eighteen percent (N=3) were not taking HIV 
medications, 70% (N=12) were taking two HIV medications, and 12% (N=2) were 
prescribed triple therapy. Infection was attributed to heterosexual activity in 47% of the 
treatment subjects (N=8), homosexual activity in 41% (N=7), blood products in 6% 
(N=l) and IV drug use in 6% (N=1). 
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Table 4.1: Baseline Characteristics a 
CONTROL INTERVENTION 
(Crisis Intervention) (Psychotherapy) 
N= 14 N= 17 
Gender 
Male(%) 13 (93) 11 (65) 
Female(%) 1 (7) 6 (35) 
Age Years 33 (29-37) 28 (26-31) 
Weight Kg 74.90kg. 69.36kg. 
CD4 count Cells/ pL 
Mean 332.57 231.82 
<200 (%) 5 (36) 10 (59) 
~ 200 (%) 9 (64) 7 (41) 
Living With Partner (%) 3 (21) 6 (35) 
Homosexual (%) 10 (71) 10 (59) 
Heterosexual (%) 4 (29) 7(41) 
Baseline HIV Drugs 
0 (%) 5 (36) 3 (18) 
2 (%) 7 (50) 12 (70) 
3 (%) 2 (14) 2 (12) 
HIV Transmission 
Heterosexual (%) 3 (21.43) 8 (47) 
Homosexual (%) 10 (71.43) 7 (41) 
Blood Products (%) 1 (7.14) 1 (6) 
IV drug use (%) 0 (0) 1 (6) 
a. Parentheses indicate 95 percent confidence intervals. 
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The characteristics of control and intervention patients for whom data was 
available at the 6-month testing interval are shown in Table 4.2. Control group subjects 
(N=12) were 92% male (N=ll), had a mean age of33 years, a mean weight of75.99 
kilograms, and mean CD4 T-cell counts of242.92 cells/J.Ll. Seventeen percent (N=2) of 
control subjects were living with a partner, and 67% (N=8) were of homosexual 
orientation. Thirty-three percent (N=4) were not taking HIV medications, 50% (N=6) 
were taking two HIV medications, and 17% (N=2) were prescribed triple therapy. 
Infection was attributed to heterosexual activity in 25% of the control subjects (N=3), 
homosexual activity in 67% (N=8), blood products in 8% (N=l) and IV drug use in 0%. 
Treatment group subjects (N=14) were 71% male (N=lO), had a mean age of29 
years, a mean weight of74.28 kilograms, and mean CD4 T-cell counts of262.15 cells/J.Ll. 
Thirty-six percent (N=S} of treatment subjects were living with a partner, and 50% (N=7) 
were of homosexual orientation. Fourteen percent (N=2) were not taking HIV 
medications, 79% (N=ll) were taking two HIV medications, and 7% (N=l) were 
prescribed triple therapy. Infection was attributed to heterosexual activity in 43% of the 
treatment subjects (N=6), homosexual activity in 43% (N=6), blood products in 7% 
(N=l) and IV drug use in 7% (N=l). 
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Table 4.2: Characteristics of Subjects with Outcome Data at Six Months 
CONTROL INTERVENTION 
(Crisis Intervention) (Psychotherapy) 
N= 12 N= 14 
Gender 
Male(%) 11 (92) 10 (71) 
Female(%) 1 (8) 4 (29) 
Age Years 33 29 
Weight Kg 75.99kg. 74.28kg. 
CD4 count Cells/ j.JL 
Mean 242.92 262.15 
< 200 (%) 6 (50) 7 (50) 
;?: 200 (%) 6 (50) 7 (50) 
Living With Partner(%) 2 (17) 5 (36) 
Homosexual (%) 8 (67) 7 (50) 
Heterosexual (%) 4 (33) 7(50) 
Baseline HIV Drugs 
0 (%) 4 (33) 2 (1 4) 
2 (%) 6 (50) 11 (79) 
3 (%) 2 (17) 1 (7) 
HIV Transmission 
Heterosexual (%) 3 (25) 6 (43) 
Homosexual (%) 8 (67) 6 (43) 
Blood Products(%) 1 (8) 1 (7) 
IV drug use (%) 0 (0) 1 (7 
80 
The characteristics of control and intervention patients for whom data was 
available at the 12-month testing interval are shown in Table 4.3. Control group subjects 
(N=8) were 87.5% male (N=7), had a mean age of33 years, a mean weight of98.9 
kilograms, and mean CD4 T-cell counts of346.38 cells/J..tl. twenty-five percent (N=2) of 
control subjects were living with a partner, and 62.5% (N=5) were of homosexual 
orientation. At baseline, 37.5 percent (N=3) were not taking HIV medications, 37.5% 
(N=3) were taking two HIV medications, and 25% (N=2) were prescribed triple therapy. 
Infection was attributed to heterosexual activity in 25% of the control subjects (N=2), 
homosexual activity in 62.5% (N=5), blood products in 12.5% (N=l) and IV drug use in 
0%. 
Treatment group subjects (N=ll) were 73% male (N=8), had a mean age of28 
years, a mean weight of74.66 kilograms, and mean CD4 T-cell counts of244.00 cells/J..tl. 
Thirty-six percent (N=4) oftreatment subjects were living with a partner, and 45.5% 
(N=75) were of homosexual orientation. Eighteen percent (N=2) were not taking HIV 
medications, 73% (N=8) were taking two HIV medications, and 9% (N=l) were 
prescribed triple therapy. Infection was attributed to heterosexual activity in 45.46% of 
the treatment subjects (N=5), homosexual activity in 36.36% (N=4), blood products in 
9.09% (N= l) and IV drug use in 9.09% (N=l). 
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Table 4.3: Characteristics of Subjects with Outcome Data at Twelve Months 
CONTROL INTERVENTION 
(Crisis Intervention) (Psychotherapy) 
N=8 N= 11 
Gender 
Male(%) 7 (87.5) 8 (73) 
Female(%) 1 (12.5) 3 (27) 
Age Years 33 28 
Weight Kg 98.9kg.a 74.66kg. 
CD4 count Cells/ j.iL 
Mean 346.38 244.00 
< 200 (%) 3 (37.5) 6(54.5) 
~ 200 (%) 5 (62.5) 5(45.5) 
Living With Partner (%) 2 (25) 4 (36) 
Homosexual (%) 5 (62.5) 5 (45.5) 
Heterosexual (%) 3 (37.5) 6(54.5) 
Baseline HN Drugs 
0 (%) 3 (37.5) 2 (18) 
2(%) 3 (37.5) 8 (73) 
3 (%) 2 (25) 1 (9) 
HIV Transmission 
Heterosexual (%) 2 (25) 5 (45.46) 
Homosexual (%) 5 (62.5) 4 (36.36) 
Blood Products (%) 1 (12.5) 1 (9.09) 
IV drug use (%) 0 (0) 1 (9.09) 
a. Weight was only available for one subject in the control group. 
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Two patients randomized to treatment withdrew immediately after the 
randomization. One patient confused it with a drug trial being offered at the same time, 
the other withdrew because of a previous negative experience in a clinical trial. One 
patient in the treatment group remained in the study but was unavailable at scheduled 
testing times because of personal travel outside the province. Over the twelve-month 
follow-up period three subjects in the treatment group, and two in the control group 
relocated and were unavailable for follow-up. 
One control patient withdrew immediately after randomization because he wanted 
to receive psychotherapy. Three patients in the control group remained in the study but 
were unavailable at scheduled testing times because of personal travel outside the 
province. 
Six-month data was available for fourteen treatment group subjects and twelve 
control group subjects whereas 12-month data was available for eleven and eight subjects 
respectively. 
4.2 Study Outcomes 
Study outcomes are detailed in Table 4.4, and illustrated in Figures 4.1 to 4. 32. 
83 
Table 4.4. P Values of Differences Between Treatment vs. Control at Baseline, Six and · 
Twelve Months a 
6 12 
Baseline Months Months 
Beck Depression Inventory 
Control 20 (15-25) b 18 (13-23) 26 (12-39) 
N 14 12 8 
Intervention 23 (18-29) b 13 (8-18) 9 (2-15) 
N 17 14 11 
P value for difference p = 0.016 p = 0.006 
Beck Hopelessness Scale 
Control 10(7-13)b 11 (8-14) 13 (8-18) 
N 14 12 8 
Intervention 10 (7-13)b 7 (4-10) 6 (2-9) 
N 17 14 11 
P value for difference p = 0.027 p = 0.005 
Coping Inventory for Stressful 
Situations 
Task 
Control 52 (47-58)b 53 (47-60) 55 (46-64) 
N 14 12 8 
Intervention 52 (45-58) b 55 (50-60) 59 (52-65) 
N 17 14 11 
P value for difference P= 0.654 p =0.214 
Emotion 
Control 50 (44-56)b 46 (40-52) 49 (40-58) 
N 14 12 8 
Intervention 51 (45-57)b 49 (43-55) 43 (36-50) 
N 17 14 11 
P value for difference P= 0.374 p = 0.059 
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Table 4.4. P Values of Differences Between Treatment vs. Control at Baseline, Six and 
Twelve Months (Continued) a 
6 
Baseline Months 
Avoidance 
Control 49 (43-SS)b 46 (45-58) 
N 14 12 
Intervention 46(40-52)b 51 (38-54) 
N 17 14 
P value for difference p = 0.036 
Distraction 
Control 25 (20-29)b 23 (19-28) 
N 14 12 
Intervention 24 (19-28) b 25 (22-29) 
N 17 14 
P value for difference p =0.221 
Social Diversion 
Control 15 (12-19)b 14 (11-17) 
N 14 12 
Intervention 15 (12-17) b 17 (14-19) 
N 17 14 
P value for difference p = 0.031 
CD4 count Cells/).!L 
333 (186-479) b Control 243(89-396) 
N 14 12 
Intervention 232 (116-347) b 262( 116-408) 
N 17 13 
P value for difference P = 0.09 
a Data are presented as means with 95% confidence intervals in parentheses. 
b There were no statistically significant differences in baseline parameters. 
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12 
Months 
46 (41-62) 
8 
52(39-53) 
11 
P= 0.062 
24 (21-28) 
8 
25 (20-30) 
11 
p = 0.331 
13 (10- 17) 
8 
17 (14-21) 
11 
p = 0.031 
346 (117 -576) 
8 
259 (115-403) 
12 
p = 0.764 
4.2.1 Depression Score Results 
Intervention patients showed a significant decrease in Beck Depression Inventory 
(BDI) scores at 6 (P = 0.016) and 12 months (P = 0.006), while no improvement was seen 
in control patients (Figures 4.1 and 4.2). 
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Figure 4.1: Beck Depression Inventory Scores in Treatment Group 
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Figure 4.2: Beck Depression Inventory Scores in Control Group 
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4.2.2 Hopelessness Score Results 
A similar pattern was observed in Beck Hopelessness Scale (BHS) scores as was 
seen in depression scores. Compared to control subjects, the intervention subjects 
receiving regular psychotherapy showed improved hopelessness scores at 6 (P = 0.027) 
and twelve months (P = 0.005) (Figures 4.3 & 4.4). 
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Figure 4.3: Beck Hopelessness Scale Scores in Treatment Group 
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Figure 4.4: Beck Hopelessness Scale Scores in Control Group 
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4.2.3 Coping Score Results 
At six months there were statistically significant differences on avoidance coping 
(P = 0.036) (Figures 4.9 & 4.10) and social diversion coping (P = 0.031) (Figures 4.13 & 
4.14), with the intervention group using more avoidance and social diversion coping. 
There was no significant difference at the six-month interval between the 
psychotherapy and crisis intervention groups on the CISS subscales: task (P = 0.654) 
(Figures 4.5 & 4.6), emotion (P = 0.374) (Figures 4.7 & 4.8) and distraction (P = 0.221) 
(Figures 4.11 & 4.12). 
The 12-month CISS subscale scores show no difference in groups on task (P = 
0.214), emotion (P = 0.059), avoidance (P = 0.062), and distraction (P = 0.331). Only 
social diversion (P = 0.031) is significant, with the intervention group using more social 
diversion coping. 
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Figure 4.5: Coping Inventory for Stressful Situations: task scores for treatment group 
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Figure 4.6: Coping Inventory for Stressful Situations: task scores for control group 
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Figure 4.7: Coping Inventory for Stressful Situations: emotion scores for treatment group 
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Figure 4.8: Coping Inventory for Stressful Situations: emotion scores for control group 
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Figure 4.9: Coping Inventory for Stressful Situations: avoidance scores for treatment 
group 
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Figure 4.10: Coping Inventory for Stressful Situations: avoidance scores for control 
group 
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Figure 4.11: Coping Inventory for Stressful Situations: distraction scores for treatment 
group 
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Figure 4.12: Coping Inventory for Stressful Situations: distraction scores for control 
group 
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Figure 4.13: Coping Inventory for Stressful Situations: social diversion scores for 
treatment group 
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Figure 4.14: Coping Inventory for Stressful Situations: social diversion scores for control 
group 
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4.2.4 CD4 T lymphocyte Counts 
There was no difference between treatment and control group on CD4+ cell 
counts at six months (P = 0.09), or 12 months (P = 0.764) (Figures 4.15 & 4.16). 
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Figure 4.15: CD4 T lymphocyte cell counts in the treatment group 
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Figure 4.16: CD4 T lymphocyte cell counts in the control group 
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4.3 Last Value Carried Forward Analysis Results 
The conclusions regarding depression, hopelessness and CD4 were unchanged 
when analyses were performed using the a priori scenario of carrying forward the last 
existing value for missing values (BDI 6, 12months; p < 0.004, p < 0.001 (Figures 4:17 & 
4.18); BHS 6, 12 months; p < 0.027, p < 0.000 (Figures 4:19 & 4:20); CD4, 6, 12 
months; p < 0.085; p < 0.395 (Figures 4:21 & 4:22). 
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Figure 4.17: LVCF Beck Depression Inventory Scores in Treatment Group 
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Figure 4.18: LVCF Beck Depression Inventory Scores in Control Group 
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Figure 4.19: L VCF Beck Hopelessness Scale Scores in Treatment Group 
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Figure 4.20: L VCF Beck Hopelessness Scale Scores in Control Group 
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Figure 4.21: LVCF CD4 Cell Counts in Treatment Group 
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Figure 4.22: L VCF CD4 Cell Counts in Control Group 
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Results of last value carried forward analyses demonstrated no differences 
between treatment and control in task coping scores at 6 months, p = 0.266, but 
significantly higher scores in the treatment group at 12mos. p = 0.010 (Figures 23 & 24). 
Results of last value carried forward analyses demonstrated no differences in 
emotion scores at 6 and 12 months, p = 0.584; p = 0.202 (Figures 25 & 26). 
Results of last value carried forward analyses demonstrated significantly higher 
avoidance scores in the treatment group at both 6 and 12 months, p = 0.015; p < 0.003 
(Figures 27 & 28). 
Results of last value carried forward analyses demonstrated no differences in 
distraction scores at 6 and 12 months, p = 0.377; p = 0.126 (Figures 29 & 30). 
Results of last value carried forward analyses demonstrated significantly higher 
social diversion scores in the treatment group at both 6 and 12 months, p = 0.008; p = 
0.001 (Figures 31& 32). 
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Figure 4.23: LVCF CISS Task Scores in Treatment Group 
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Figure 4.24: L VCF CISS Task Scores in Control Group 
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Figure 4.25: LVCF CISS Emotion Scores in Treatment Group 
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Figure 4.26: L VCF CISS Emotion Scores in Control Group 
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Figure 4.27: LVCF CISS Avoidance Scores in Treatment Group 
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Figure 4.28: LVCF CISS Avoidance Scores in Control Group 
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Figure 4.29: L VCF CISS Distraction Scores in Treatment Group 
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Figure 4.30: LVCF CISS Distraction Scores in Control Group 
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Figure 4.31 : L VCF CISS Social Diversion Scores in Treatment Group 
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Figure 4.32: LVCF CISS Social Diversion Scores in Control Group 
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4.4 Adjusted Analysis of Baseline Differences 
The linear regression analysis, adjusting for gender, age, marital status (described 
as living with partner in table 4.1 ), sexual orientation and route of transmission yielded 
similar findings to the primary analysis. None of the variables was significantly related to 
the 6-month change in depression. Only treatment and stratification were associated with 
change in BDI at six months. 
An adjusted analysis of the secondary outcome measures yielded no meaningful 
differences between the results obtained from the primary analysis. The mean CISS 
Avoidance 12-month scores was significantly higher in the treatment group. Though 
statistically significant, this change was a clinically unimportant difference since values 
for both groups fell in the same diagnostic category. 
4.5 ANCOV A Without Stratification As Covariate 
The ANCOV A of the primary and secondary outcome measures, without 
stratification as a covariate, yielded results similar to the ANCOV A with stratification as 
a covariate. 
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5.1 BDI Related Outcomes 
CHAPTERS 
DISCUSSION 
The current study, unlike the majority of related studies, examined the impact of 
psychotherapy in a heterogeneous population of persons living with HIV/AIDS. Most 
studies enrolled patients who were male, gay or bisexual. This study enrolled males and 
females, heterosexuals and homosexuals. Generally, the trials investigating the efficacy 
of psychotherapy in HIV either included only subjects who had depression scores in the 
moderate/severe range, or had scores indicating mild depression. Subjects had BDI 
scores ranging from mild to severe (BDI scores 2-41). Numerous trials excluded HIV 
patients who were symptomatic and no RCTs investigating psychotherapy and HIV could 
be found which included patients with AIDS. In the trial reported in this thesis CD4 cell 
counts were used as a marker of disease severity and trial subjects ranged from 
asymptomatic to AIDS (CD4 cells/mm3 879-0). Most of the RCTs in the literature 
excluded subjects with a history of a major psychiatric disorder. Patients with previous 
psychiatric disorders were included in this thesis trial. The majority of related trials 
investigated the provision of psychotherapy for periods of under 4 months duration. This 
thesis reports findings of the intervention group subjects who were provided 
psychotherapy for 12 months. 
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The primary goal of this trial, was to examine psychotherapy in the context of the 
management of persons living with HIV disease, not limit its investigation to selected 
subgroups of HIV positive patients. From the clinical team experience with HIV 
patients, many presented with histories of psychiatric disorders, dysfunctional personal 
relationships, physical abuse, drug and alcohol abuse, etc. It was the team belief that, for 
many of the patients, HIV was exacerbating previous or existing problems, not the sole 
cause of decreased psychological well-being. Team members also observed that patients 
reported feelings of depression and/or hopelessness independent of disease 
symptomology, indicating that improving physical outcomes alone may not ensure 
improved psychological well-being. In Newfoundland and Labrador the proportion of 
females and heterosexuals was higher than the proportions observed nationally, and it 
was felt that these groups should be represented in a clinical study, at least to the degree 
that subjects were available. The small population of Newfoundland and Labrador 
presented challenges for patients to keep their HIV immune status unknown and the 
clinical team felt th;;tt psychotherapy might be beneficial in addressing the psychological 
stress associated with forced or unplanned disclosure. It was felt that these outcomes 
might be associated with depression, and in conjunction with the psychological burden 
associated with living with HIV and AIDS, suggest a role for psychotherapy in the 
management ofHIV disease 
Measures of the severity of depression at six months showed that patients in the 
intervention group had scores that were indicative of mild depression, whereas patients in 
the control group had scores indicating moderate depression. 
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After 12 months of psychotherapy there was an even greater difference in mean scores 
between the treatment and control group. The treatment group had depression scores in 
the minimal range, whereas control group subjects had scores in the high end of the 
moderate range. There was a systematic decline in depression scores in the treatment 
group, whereas there was an increase in depression scores from baseline to 12 months in 
the control group. 
Beck depression scores above 15 are thought to be indicative of depression that 
may require a clinical intervention. At both the six-month and 12-month intervals, the 
mean BDI scores did not indicate depression that may require clinical intervention in the 
treatment group, but suggest depression warranting clinical intervention in the control 
group. 
5.1.1 Discussion of Studies Related to HIV and Depression after 1996 
Chapter two presented a review oftrials up to 1996, that were related to the thesis 
primary outcome measure of depression in HIV positive patients. At that time, there was 
a less clear role for psychotherapy in the management of HIV I AIDS. There was an 
absence of consistent and reliable information to identify if there was benefit to the 
provision of psychotherapy in managing depression in HIV positive patients, and which 
groups of patients, if any, might benefit from psychotherapeutic interventions. In this 
section I wish to evaluate some ofthe trials published after the commencement ofRCT 
discussed in this thesis. 
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Table 5.1 provides a comparison ofthe trials discussed at length in this thesis, 
which were related to the primary outcome. Generally, the trials support a role for 
psychotherapy in the management ofHIV. Group therapy orientations dominate the 
literature but improvements in depression have been observed from the provision of 
individual psychotherapy. In only one of the studies was there no benefit of 
psychotherapy in reducing psychological distress and the outcome was most probably 
related to a ceiling effect. Many of the studies were weakened by the absence of a 
control group, bringing into question the strength of the conclusion that psychotherapy 
ameliorates depression in persons living with HIV. The randomized controlled nature of 
the thesis RCT provides confidence in the conclusion ofbenefit of psychotherapy in the 
management of depression and hopelessness in persons living with HIV AIDS. 
Antoni eta/. (2000) investigated the effects of a cognitive-behavioral stress 
management (CBSM) intervention on anxiety, 24-hour Urinary Norepinephrine output 
and T -cytotoxic suppressor cells in symptomatic HIV- infected gay men. Participants 
were randomized to either a 10-week group based manualized CBSM treatment condition 
or wait-list control. Only 74 of the 96 men completed the study but were similar at 
baseline to those who did not, and equal proportions of subjects in both groups were 
noncompleters. There were no significant differences in baseline measures between 
groups. 
Mood measures were assessed by the Profile of Mood States (POMS) and the 
Perceived Stress Scale (PSS). Compared to the control group, men assigned to CBSM 
showed significantly lower post treatment levels of self-reported anxiety, anger, total 
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mood disturbance, and perceived stress; and less norepinephrine (NE) output. The 
authors also state that at the individual level, anxiety decreases paralleled NE reductions. 
Additionally, significantly greater numbers ofT-cytotoxic/suppressor (CD3+/CD8+) 
lymphocytes were found six to 12 months later in subjects assigned to CBSM. The 
authors also demonstrate that greater decreases in NE output and a greater frequency of 
relaxation home practice during the 1 0-week CBSM intervention period predicted higher 
CD3+/CD8+ cell counts at follow-up. 
The authors were unable to demonstrate any significant differences in 
CD3+/CD4+ or CD3+/CD8+ cell counts immediately following the intervention. This is 
consistent with this researchers RCT finding of non-significant differences between 
groups on CD4 cell counts. Both this study and the thesis RCT may not have been 
sufficiently powered, due to small sample sizes, to detect immune marker differences. 
Enrollment in this trial was very restrictive. Subjects were gay, had relatively 
asymptomatic HIV infection, had minimal psychological problems, including no major 
depressive disorder, and no drug or alcohol dependency. Subjects were all college 
educated and had full time employment. This clearly restricts generalizations from the 
study findings, particularly to HIV positive heterosexuals, HIV positive females, HIV 
positive patients with psychiatric problems, patients with AIDS, less educated HIV 
positive patients and unemployed HIV positive patients. 
Less than 37 % (N=35) of the trial subjects had follow-up data. This brings into 
question the validity ofthe authors' conclusion of significantly higher CD3+/CD8+ cell 
counts favouring the CBSM group. 
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Depression was measured using the Hamilton Rating Scale for Depression 
(HRSD) but the authors state depression was not an outcome of interest but used to 
screen subjects. Subjects with corrected HRSD scores greater than 15 were excluded 
form the trial limiting specific comments regarding the effectiveness of CBSM on 
depression. 
Depression score change was the primary outcome of the thesis RCT, and the lack 
of reporting of this outcome by Antoni et a!. prevents this researcher from drawing 
parallels in relation to depression. Both this trial and that of the thesis author suggest 
improvements in psychological well-being through the provision of psychotherapy. 
However, Antoni et al. used a group model with a selected homogenous population 
whereas this researcher used an individual psychotherapy model with a heterogeneous 
population. These two differences limit comparisons of the two trials. 
A RCT was conducted by Goodkin et al. (1999) to assess the effects on 
psychological distress and grief of a bereavement support group intervention in HIV 
seropositive and seronegative homosexual men. A total of 197 subjects were randomized 
to either a bereavement support group intervention or a community standard of care 
control condition. Thirty-one subjects did not complete the study follow-up, however all 
were accounted for. 
The Texas Inventory of Grief (TIG) was used to measure grief level and the 
POMS was used to assess distress. A grief overall distress composite score was derived 
from the two tests producing a score representing the outcome variable, distress. The 
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Structured Interview Guide for the Hamilton Anxiety and Depression (SIGH-AD) rating 
scale was used as a secondary distress outcome measure to supplement the POMS. 
After the intervention the bereavement experimental group had significantly 
lower distress scores than the control group. The authors conclude a brief group 
intervention can significantly reduce overall distress and accelerate grief reduction in a 
sample ofbereaved subjects. However there was no significant difference post-
intervention between groups on clinically rated depression and anxiety, assessed with the 
HRSD and Hamilton Anxiety Rating Scale (HARS). The authors conclude this may have 
been due to the relatively compressed range of variation observed on these measures in 
this sample, which was less depressed than a typical clinical population. This finding 
limits conclusions regarding the benefits ofbereavement support groups with more 
severe distress and psychopathology. Both this study and the thesis RCT support a 
beneficial role for psychotherapy in the treatment of psychological issues confronting 
persons living with HIV. 
The finding of no difference in depression scores post treatment is contrary to the 
findings in this thesis RCT. The short term nature ofthe Goodkin eta/. trial and the fact 
that it is a group psychotherapy format, limits comparisons with the thesis RCT, which 
was long term individual psychotherapy. 
All the subjects were homosexual males, generally healthy, and had no history of 
past or current psychiatric disorders. This limits generalizabilty of the study findings to 
HIV positive heterosexuals, HIV positive females, and severely ill HIV positive 
populations. 
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Weiss et a!. ( 1999) investigated the effects of a 4-month supportive-expressive 
group (SEGT) intervention in 85 HIV positive gay men. Subjects were assessed using the 
BDI and the Hopkins Symptom Checklist (HSCL). The authors found no significant 
differences on distress, coping, or social support between the treatment group receiving 
supportive-expressive interventions and written material and the control group, which 
only received the written materials. The authors conclude that in the absence of clear 
indications for treatment, supportive-expressive group intervention may be no more 
effective at reducing distress than is provision of the written information. 
All trial subjects were asymptomatic gay males making it difficult to determine 
the effects of supportive-expressive group therapy in HIV positive heterosexuals, HIV 
positive females and less healthy HIV positive populations. 
The findings of no group differences in distress or social support are contrary to 
both the RCT findings of this researcher and other authors reported in this thesis. In 
discussion with the principal author he noted that the patients in this study had minimal 
distress scores at the start of the trial, therefore it may not have been possible to detect 
differences in distress due to a "ceiling" effect. 
In an RCT to compare the effect of a CBSM on distress outcomes Lutgendorf et 
al. (1998) randomized 40 HIV+ gay men to either a 10-week CBSM intervention or 10-
week wait-list control. Patients' mood was assessed using BDI and POMS; coping ability 
using COPE and perceptions of social support using the Social Provisions Scale (SPS). 
Patients were mildly symptomatic; free of AIDS symptomology, had no present or 
previous major psychiatric disorders, and were not clinically depressed. No significant 
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differences were observed between the groups at baseline. After completion of the 10-
week CBSM intervention there were significant differences in the social supports and 
cognitive coping strategies favouring the treatment group. The authors conclude a CBSM 
group intervention can significantly attenuate dysphoria, anxiety and total mood 
disturbance in symptomatic HIV seropositive gay men. 
The authors did not present data directly related to comparisons between 
intervention and control groups on measures ofBDI or POMS. Instead authors were 
interested in correlations with BDI and POMS on subscales of COPE and SPS. The 
authors observed that increased acceptance and increased positive reframing was 
significantly associated with lower POMS depression, anxiety and total mood disturbance 
(TMD) and lower BDI depression at 10 weeks. They also observed that increased active 
coping was correlated with decreased distress but not correlated with changes in BDI 
scores. Denial coping was not significantly associated with distress. Increases in SPS 
scales of attachment, guidance, reliable alliance and social integration were significantly 
associated with lower POMS anxiety, depression, and TMD but not BDl. 
In the absence of direct comparisons of mood measures between the treatment 
and control groups, only very limited comparisons can be made between the Lutgendorf 
trial and the thesis RCT. There does appear to be mood related improvements in both 
studies, which are related to the provision of psychotherapy. 
Lutgendorf eta/. acknowledged that small sample size might have limited their 
ability to detect differences and that some of the non-significant results are probably 
attributable to the small number of subjects. 
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Lutgendorf et al. utilized group psychotherapy whereas the RCT discussed in this 
thesis was individual psychotherapy, limiting comparisons between the two studies. 
Because the sample was restricted to men who were free of major mental health problems 
it is unclear what role this group intervention would have in treating patients with more 
severe mental problems. 
With only HIV positive gay male subjects there are limitations to the 
generalizabilty of the findings to HIV positive females and HIV positive heterosexuals. 
Most subjects were college educated and employed and it is uncertain how this 
intervention might impact less educated or unemployed subjects. In addition, using only 
mildly symptomatic subjects does not address the effectiveness of this intervention on 
moderately ill or severely ill patients. 
Markowitz et al. (1998) randomized 101 HIV-positive subjects, with significant 
depressive symptoms, to 16-week interventions comparing interpersonal psychotherapy 
(IPT) (N=24), cognitive behavioural therapy (CBT) (N=27), supportive psychotherapy 
(SP) (N=24) and supportive psychotherapy with imipramine (SWI) (N=26). Depressive 
symptomology was assessed using the BDI and the Hamilton Depression Rating Scale 
(HAM-D). The authors observed that subjects randomized to interpersonal psychotherapy 
and supportive psychotherapy with imipramine had significantly greater improvement on 
depressive measures than those receiving supportive psychotherapy or cognitive 
behavioral therapy. The authors suggest that depressive symptoms appear treatable in 
HIV positive patients and that IPT may have particular advantages as psychotherapy for 
HIV patients with depressive symptoms. 
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The authors suggest their supportive psychotherapy group approximate a control 
group however, it clearly is not a control group, at least in an epidemiological sense. This 
trial is a comparison of psychotherapies more so than an investigation of the impact of 
psychotherapy on depression in persons living with HIV. 
All subjects had to score 15 or higher on Hamilton Depression Rating Scale 
(Ham-D) and have a clinical judgment of significant depressive symptoms. Subjects were 
rated "relatively medically asymptomatic." Females accounted for 15% of the trial 
sample and 80% of the subjects were gay or bisexual. This limits generalizabilty of the 
finding to less severely depressed HIV positive patients, HIV positive women and HIV 
positive heterosexuals. In the RCT presented in this thesis, a heterogeneous patient 
sample was enrolled with no exclusion criteria related to scores on standardized 
depression scales. 
Markowitz et al. demonstrated no significant difference on baseline 
measurements between groups. At midpoint and at termination, scores on the Ham-D 
decreased significantly for all treatment groups. BDI scores fell significantly by midpoint 
for IPT and SWI and for all groups by termination. A similar finding of decrease in BDI 
scores favouring psychotherapy was shown in this thesis RCT. There was no difference 
in CD4 cell counts amongst the groups at the conclusion of the trial. A similar finding 
was observed in this thesis RCT. 
There was no follow-up reported in this study so little can be said about the 
longer-term effects ofthese interventions in controlling depression. The authors claim the 
relatively small sample size might have reduced statistical power to detect treatment 
119 
differences. The authors did not account for the absence of the 32 patients not included in 
their analysis of trial completers. Minimal information, only that 4 patients refused 
randomization and 15 completed < 4 sessions was provided. A thorough reporting of the 
trial subjects would have enabled a more critical appraisal of the authors' conclusions. 
Zisook et al. (1998) conducted a randomized double-blind, placebo controlled 
trial to compare the efficacy and safety of fluoxetine plus group psychotherapy versus 
group psychotherapy alone. The 47 subjects enrolled were referred from either a cohort 
of 500 subjects being followed by the University of California, San Diego (UCSD) HIV 
Neurobehavioral Research Centre (HNRC) or the UCSD outpatient psychiatry services. 
Subjects were HIV -seropositive males and currently experiencing a major depressive 
episode of moderate to severe intensity. 
Subjects were randomized to a fluoxetine group or placebo group. All subjects 
were exposed to a seven-week group supportive psychotherapy treatment phase following 
randomization. 
By endpoint the intervention patients treated with fluoxetine experienced greater 
mean reductions from baseline compared to the placebo group on HAM-D and BDI-13 
depression measures. Subjects who were treated with fluoxetine showed significantly 
more improvement on self and observer rated depression by the end of the first week of 
treatment. The authors conclude this study supports the efficacy and safety of fluoxetine 
over and above group psychotherapy alone for the treatment of HIV -associated major 
depression. It can not be concluded from this study that there would be advantages of 
fluoxetine over psychotherapy in patients with less severe depression. In addition it is 
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difficult to compare the Zisook et al. trial with the thesis RCT since the former is a group 
intervention and the latter is individual psychotherapy. 
The authors acknowledge theirs was not a true placebo controlled trial in that all 
subjects received supportive psychotherapy and the trial was not designed to test the 
efficacy of group psychotherapy. The presence of a control group receiving no 
psychotherapy would have permitted an examination of the efficacy of group 
psychotherapy. In addition, the authors note that a more structured, systematized form of 
group therapy might have further improved the efficacy of the group therapy plus placebo 
cohort. 
The authors compared a subgroup of patients with major depressive diagnosis of 
mild severity and found significant decrease in depression scores in both groups. The 
authors conclude that group psychotherapy may be sufficient for the treatment of major 
depressive episode of mild severity, but medications are an important component of 
treatment for more severe episodes. This finding supports a role for psychotherapy in the 
management of depression and is consistent with the findings of this thesis RCT. 
In a randomized controlled trial comparing the influence of interpersonal 
psychotherapy (IPT) on psychosocial variables and immune function in depressed males! 
Gruettert et al., (1998) found IPT to significantly reduce psychological distress. The 
authors found no significant psychoimmunological effect of psychotherapy. These 
findings related to the provision of psychotherapy are consistent with the finding in this 
thesis RCT. 
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The authors report IPT has advantages over supportive therapy, which is 
inconsistent with other reports, which clearly demonstrates a consistent failure to show 
one psychotherapy to offer any advantage over another (Brown, 1996). Despite efforts to 
locate a published article for this abstract, one could not be found. 
Lutgendorf et al. (1997) investigated the effects of a 1 0-week group cognitive-
behavioral stress management intervention on mood and immunologic function in 52 
HIV -seropositive gay men. All patients were symptomatic but none had a diagnosis of 
AIDS. Only 40 subjects completed the trial but there was no difference in the proportions 
lost in each group. Subjects were randomized to the treatment group or wait-list control. 
All participants' psychological measures were assessed with the BDI and POMS. Blood 
samples were taken on all patients. There were no significant differences between 
subjects at baseline. 
The treatment group subjects showed significant decreases in self reported 
dysphoria, anxiety, and total distress as well as significant decreases in herpes simplex 
virus - type 2 (HSV -2) antibody titers. The BDI scores were significantly lower at post 
intervention compared to the control group. This finding is consistent with the thesis 
RCT. A problem with the Lutgendorf et al. study is that subjects were involved in outside 
therapy and support groups and it is unclear what effects these interventions had on the 
CBSM group. 
There were no significant differences between treatment and control groups on 
CDS+ and CD4+ cell counts. The finding regarding CD4+ cell counts is consistent with 
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the results reported in the thesis RCT. The small sample sizes ofboth these trials may 
have limited the ability to detect differences in CD4 cell counts. 
The homogeneity of the trial subjects limits the generalizabilty of the findings to 
HIV positive heterosexuals, HIV positive females and people with AIDS. 
The authors conclude that even in progressed symptomatic HIV disease, stress 
management interventions may enhance psychological adjustment and influence the 
immune system in a meaningful way. The authors' statement regarding immune function 
improvement is not strongly supported by their trial results. 
The author of this thesis RCT concludes that provision of individual 
psychotherapy is effective in ameliorating depression in a heterogeneous population of 
persons living with HIV/AIDS. In addition, the author feels that routine psychotherapy, 
as a component of HIV disease management may have a preventive effect on depression. 
123 
Table 5.1: Comparison of Trials Related to Thesis RCT Primary Outcome 
Reference Subjects Intervention Measure Effect 
Antoni et al. Gay males CBSM group therapy POMS + 
2000 N = 96 (74) I vs. control PSS + 
10 weeks NE output + 
CD3+CD8+ + 
Goodkin et al. Gay males Bereavement support TIG/POMS + 
N = 197 (166) I group therapy vs. SIGH-AD NS 
control 
10 weeks 
Weiss et al. Gay males SE group therapy vs. BDI NS 
1999 N=85 control HSCL NS 
Conference 16-weeks 
report 
Lutgendorf et Gay males CBSM group therapy COPE + 
al. 1998 N =52 (40) I vs. control SPS + 
10 weeks 
Markowitz et al. Males IPT, CBT, SP, and SWI BDI +4 
1998 N=85 16 weeks HAM-D +4 
Females CD4+ NS 
N=15 
80% gay/bi 
Zisook et al. Males SP group therapy + HAM-D + 
1998 47 (37) I Fluoxetine vs. SP BDI-13 + 
7 weeks 
Gruettert et al. 2 Males j IPTvs. SP Psychosocial + 
1998 CD4+ NS 
_{Abstract)_ 
Lutgendorf et Gay males CBSM group therapy BDI + 
al. 1997 N = 52 (40) I vs. control POMS + 
10 weeks HSV-2 + 
HSV-1 NS 
CD4+ NS 
CD8+ NS 
Markowitz et al. Gay/Bi males IPT vs. SP BDI +4 
1995 N = 32 (30) I 16 weeks HRSD +4 
Target al. Gay males ST group therapy + HAM-D + 
1994 N = 20 (18) I Fluoxetine vs. ST for POMS + 
12 weeks CD4+ NS 
CD3+ NS 
Mulder et al. Gay males CBT group therapy, ET BDI + 
1994 N = 39 (27) I vs. Control GHQ + 
15 weeks POMS + 
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Table 5.1: Comparison of Trials Related to the Thesis RCT Primary Outcome 
(Continued) 
Reference Subjects Intervention 
Kelly et al. Males CBT group therapy, 
1993 94% gay/bi SST vs. control 
N = 115 (68) 1 8 weeks 
Markowitz et al. N=23 IPT 
1992 16 weeks 
Mugford thesis N = 31 (26) I Psychotherapy vs. 
RCT control 
26 weeks 
1 Number of subjects included in analysis of primary outcome. 
2 No article could be found. 
3 Number of subjects not reported in abstract. 
Measure 
CES-D 
SPS 
SCL-90-R 
MHLCS 
HRSD 
BDI 
BHS 
CISS 
CD4+ 
4 There was significant difference between baseline scores and endpoint scores. 
5 Some subscales were statistically significant but no scales were clinically significant. 
5.2 BHS Related Outcomes 
Effect 
+ 
+ 
+ 
+ 
+4 
+ 
+ 
NS5 
NS 
This thesis study also examined the efficacy of long-term psychotherapy on 
hopelessness. At six months the treatment group had scores that indicated mild 
hopelessness whereas the control group had scores in the moderate range. 
This finding of improvement in hopelessness scores favouring the treatment group 
at the six-month interval is again observed at the 12-month period. Over the 12-month 
period scores in the treatment group continue to decline whereas scores in the control 
group are not only higher than the treatment group but continue to increase from baseline 
levels. 
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Hopelessness scores of nine or more are reported to be a predictor of eventual 
suicide in depressed people with suicide ideation. Therefore the decrease in hopelessness 
scores resulting from the psychotherapy intervention is an even stronger recommendation 
for its use in HIV management. 
5.2.1 Discussion of Studies Related to HIV and Hopelessness 
A search of the literature for RCTs investigating the efficacy of psychotherapy on 
hopelessness in persons living with HIV I AIDS revealed no trials where hopelessness is 
measured independently. Hopelessness is discussed in some trials, but only as component 
of depression, and was generally measured on a subscale of distress and mood state 
measures. This thesis RCT is the only known RCT to measure hopelessness directly as 
an outcome variable distinct from depression or distress in examining the efficacy of 
psychotherapy. 
Despite the lack ofRCTs investigating hopelessness, terms such as hope, despair 
or hopelessness were detected in several reports, as important elements in the lives of 
persons with HIV or AIDS (Kylma eta/., 2001). Feelings ofhopelessness may be 
present at varying times throughout the course ofHIV disease. Kylma eta/. (2001) 
indicated the need for further research on the dynamics of hopelessness in persons living 
with HIV/AIDS. The author of this thesis trial observed measurable increases in 
hopelessness over time in the HIV positive control subjects. 
126 
Rabkin eta!. (2000) investigated the psychological effects of highly active 
antiretroviral therapy (HAART) on 173 HIV+ gay or bisexual men with symptomatic 
HIV illness. The subjects had mild to moderate distress assessed using the Structured 
Clinical Interview for DSM-IV, BDI, Endicott Quality of Life Enjoyment and 
Satisfaction Questionnaire, and BHS. Generalized mental health improvement was not 
related to individual medical improvement of markers of HIV illness progression. 
Patients classified as medically improved were no more likely than those who remain 
unimproved to report greater decline in measures of distress and hopelessness. The 
authors concluded that patients whose CD4 cell count and HIV RNA viral load reflected 
successful treatment were no more likely than others to be relieved of the psychological 
burden of illness. The finding by Rabkin eta!. of a weak association between medical 
improvement markers and decline in hopelessness and distress is consistent with the 
findings of the thesis RCT, of no difference in CD4 cell counts despite significant 
reductions in depression and hopelessness scores. 
This trial was not an investigation of the efficacy of psychotherapy but an 
investigation of the impact of antiretroviral therapy on measurements of psychological 
distress. Only very limited comparisons between this trial and the thesis RCT are 
possible. This trial was included, however, because it provides relevant information 
which suggests that the improved physical health related to the provision of antiretroviral 
therapy may not be sufficient to improve psychological distress associated with living 
with HIV and AIDS. 
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Swindells et al. (1999) in an observational study followed 138 HIV positive 
patients and compared measures ofhopelessness, coping and quality of life (QOL) with 
perceived satisfaction with social support. The authors concluded hopelessness, emotion-
focused coping, avoidant coping and AIDS were predictors of poor QOL. They also 
found that employment, higher income, satisfaction with social support, and problem-
focused coping were associated with significantly better QOL. They suggested that 
interventions to alleviate hopelessness, maladaptive coping and enhancement of 
satisfaction with social support may improve overall QOL in HIV -infected patients. 
Psychotherapy may be conceptualized as containing aspects of social support and the 
provision of psychotherapy significantly reduced hopelessness in the treatment group of 
the thesis RCT, supporting the conclusions of Swindells et al.. 
In a study to assess the effects of 12 weeks of fluoxetine on mood and immune 
status in depressed patients with HIV, Rabkin eta/. (1994) treated 23 patients with either 
fluoxetine alone or fluoxetine plus dextroamphetamine. Patients were assessed using the 
HRSD, Brief Symptom Inventory, Clinical Global Impressions Scale and BHS. All 
patients experienced decreases in psychological distress. There was no effect of 
fluoxetine on CD4 cell counts. The authors conclude fluoxetine alone and fluoxetine plus 
dextroamphetamine were an effective treatment for patients with HIV illness and Axis I 
depression. This thesis authors observed a similar finding of minimal impact on CD4 cell 
counts with successful management of depression and hopelessness. A similar problem in 
both the thesis RCT and the study by Rabkin et a/. is insufficient power to detect 
significant changes in immune markers. 
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Van-Servellen eta!. (1993) presented a paradigm for viewing mental health states 
of depression and hopelessness as outcomes that are dependent on stressors, physical 
health states, and stress-resistance resources. From psychological assessments and 
interviews of 30 males with AIDS, the authors report satisfaction with social support, 
intrapersonal hope and global hope were all significantly negatively associated with 
hopelessness. The authors also reported a significant positive relationship between 
negative life events and the measure of depression and number of complications. The 
authors concluded, depression and hopelessness are major problems in persons with 
AIDS and stress-resistance resources are important in promoting mental health. 
Developing stress resistance skills may be viewed as an aspect of psychotherapy and with 
this conceptualization in mind, the thesis RCT finding of decreased hopelessness in 
response to psychotherapy is consistent with the paradigm presented by V an-Servellen et 
al. 
Catalan eta!. (1992) compared the prevalence of psychosocial problems in a 
cross-sectional study of24 HIV positive and 25 HIV negative gay men. The authors 
concluded that psychological morbidity was associated with hopelessness, previous 
psychiatric illness, symptomatic HIV disease and low self-esteem. Comparisons of 
findings of this study to that of the thesis RCT are limited by the nonexperimental nature 
of Catalan et al. trial and the differences in intent of both groups of authors. However the 
author of this thesis RCT observed decreases in depression and hopelessness as a result of 
the provision of psychotherapy and decreases in depression paralleled decreases in 
hopelessness. 
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Using CD4 cell counts as a measure of disease severity, the author of this thesis 
RCT did not observe a strong relationship between hopelessness and symptomatic HIV 
disease. Patients who demonstrated significant decrease in both measures of 
psychological morbidity, depression and hopelessness, did not differ on disease severity 
measures compared to the control group who were observed to have significantly higher 
levels of depression and hopelessness. 
In conclusion, the provision of psychotherapy was effective in ameliorating 
hopelessness in a heterogeneous population of persons living with HIV/AIDS. In 
addition the availability of routine psychotherapy throughout the disease course may have 
had a preventive effect in relation to feelings of hopelessness. A decrease in feeling of 
hopelessness can motivate patients to take control of their lives and pursue a course 
which will enhance their quality of life. It is conceivable that believing there is no hope 
for the future and nothing good can ever happen, both aspects of hopelessness, will 
inhibit processes which promote quality of life. Significantly decreasing hopelessness is 
likely to motivate patients to make choices that will enhance their lives. 
5.3 Coping Related Outcomes 
In the specific application of coping to depression, the results of a number of 
studies have shown that depressed individuals use more emotion related coping behaviors 
than nondepressed individuals (Billings and Moos, 1984; Endler and Parker 1990b ). In 
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addition there is empirical evidence for a negative relationship between depression and 
task-oriented coping behaviors (Mitchell and Hodgson, 1983). 
An examination of the subscales of the Coping Inventory for Stressful Situations 
(CISS) using the interpretative guidelines established by Endler and Parker (1990a) 
provided an overview of the coping skills of patients in this thesis clinical trial. At 
baseline, both treatment and control group scores are in the average range for task and 
social diversion. The psychotherapy group was in the average range for avoidance 
whereas the control group was in the slightly above average range. Both groups are in the 
slightly above average range for emotion and distraction. 
At the 6-month interval subjects in both groups scores were in the average range 
for task, emotion and social diversion. Scores were in the slightly above average category 
for avoidance and distraction subscales. Despite the finding of a statistically significant 
difference on raw scores for avoidance coping at the 6-month interval, both the 
intervention group score and control group score fall into the category "slightly above 
average". 
By 12 months, both groups were in the average range for task, emotion and social 
diversion, and both groups were in the slightly above average on avoidance and 
distraction. 
The avoidance scale and the two A voidance subscales, distraction and social 
diversion, are not correlated with depression (Endler and Parker, 1990a), thus little 
infonnation is gained from the differences between treatment and control scores on 
avoidance coping at the 6-month interval. 
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5.3.1 Discussion of Studies Related to HIV and Coping 
A literature search for RCTs, coping, HIV/AIDS, and CISS yielded very limited 
information. A review of these articles suggests a relationship between coping and 
psychological well-being. Uehara eta/, 1999 looked at the relationship between stress 
coping, as measured by CISS, and personality in 60 outpatients who were in remission 
from major depressive disorder. Their findings supported current opinions that coping is 
related to the pathology and course of mental disorders. They found task-oriented coping 
to be related to extraversion and frustration tolerance, whereas emotion-oriented coping 
was closely associated with neuroticism, esoteric tendencies, and isolation tendencies. 
In a study using a pretest-posttest design Heckman et a/. looked at providing a 
coping improvement intervention to 16 older adults living with HIV/AIDS. Though this 
trial is weakened by the absence of a control group, the authors concluded that the 
provision of the coping skills training intervention increased participants' perceptions of 
social support, produced higher perceptions of social well-being, and enabled more 
planful problem solving, confrontive coping and future optimism. 
In an effort to determine whether quality oflife (QOL) in patients with HIV is 
influenced by satisfaction with social support, coping style and hopelessness Swindells et 
a/. (1999) studied 138 HIV positive patients. Amongst their findings were that problem 
focused coping was associated with significantly better QOL, whereas emotion focused 
coping, avoidant coping, and hopelessness were predictors of poorer QOL. 
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In a trial investigating the effects of coping skills training on 40 symptomatic HIV 
gay males Lutgendorf et al. (1998) found that cognitive coping training was strongly 
related to lower dysphoria, anxiety and total mood disturbance in the intervention group 
compared to the controls. In this thesis RCT no significant relationship was observed 
between coping scores and significant decreases in depression and hopelessness. 
Significant correlations between ineffective coping and low quality of life have 
also been demonstrated by Leiberich et al. (1997). From their study of61 HIV positive 
persons in all stages of infection, they conclude that after an initial phase of sorrow and 
lack of orientation regarding their future life, most HIV positive persons deal effectively 
with the demands ofiDV infection but HIV positive patients with a high degree of 
distress and evasive regressive coping patterns need professional support such as 
psychotherapy. 
Normative data have not yet been established for the CISS scores in HIV 
populations. It is therefore impossible to compare the results of this thesis RCT with a 
normative sample. The thesis author feels the CISS scale would be more appropriately 
used to examine how individual patients are doing compared to a normative sample. In 
addition, it is likely that there were insufficient numbers of patients to test some of the 
subgroup comparisons. 
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5.4 CD4 T -lymphocytes Related Outcomes 
The finding of no significant difference between the treatment and control groups 
at six and 12 months was expected since the author was aware that the study would not 
have the power to detect significant changes in CD4 cell counts. The majority of the trials 
reporting the impact of psychotherapy on immune markers appear to be insufficiently 
powered to detect significant change. 
5.4.1 Discussion of Studies Related to HIV T -lymphocytes 
It has often been surmised that improved psychological well-being in the 
medically ill would lead to improvement in immune function. A review of the literature 
reveals conflicting opinions regarding the effects of psychotherapy on immune responses. 
Though some studies have not shown improved immune function directly related to the 
provision of psychotherapy there is evidence demonstrating psychotherapy leads to 
improved immune function (Cruess, et al., 2001). Much ofthe early literature utilizes 
weaker research designs and small sample sizes. There is a need for randomized clinical 
trials which are sufficiently powered to examine the efficacy of psychotherapy in 
improving CD4 T cell production 
Antoni et al. (2002) examined the effect of a stress management model of 
psychotherapy on immune system reconstruction in 25 HIV -infected males. The authors 
found that the group receiving stress management had higher CD4+/CD45RA+/CD29+ 
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cell counts at follow-up compared to the control group. This was independent of initial 
number ofT cells and the HIV virus load. In this thesis RCT no differences were 
observed on CD4 cell counts between treatment and control subjects. 
Mohr et al. (2001) examined the relationship between the alleviation of 
depression and interferon gamma (IFN-gamma) production by peripheral blood 
mononuclear cells in patients diagnosed with relapsing-remitting multiple sclerosis (MS) 
and major depressive disorder. They concluded the production of the proinflamatory 
cytokine IFN-gamma in relapsing-remitting MS is related to depression and treating the 
depression resulted in decreased IFN - gamma production. 
Antoni et al. (2000) found that HIV positive gay men assigned to a group based 
cognitive behavioral stress management (CBSM) intervention had significantly lower 24-
hour urinary norepinephrine levels and decreased anxiety compared to the control group. 
In addition they found that the men with the greatest reductions in distress and 
norepinephrine level at 10 week follow-up had greater numbers ofT-cytotoxic/suppressor 
(CD3+/CD8+) cells at 1-year follow-up. 
In a two group comparison of 35 astlunatic children, the group receiving a 6-
month psychosocial intervention in addition to conventional antiastlunatic therapy 
showed significant reduction in the specific Immunoglobulin E (IgE) responses against 
Ascaris lumbricoides (intestinal parasite), a significant increase in natural killer (NK) 
cells, an augmented expression of the T -cell receptor for Interlukin 2, and a significant 
decrease ofleukocytes with low affinity receptors for IgE (Castes et al., 1999). 
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In a study of26 asymptomatic HIV positive homosexual men Mulder et al. (1995) 
found no differences in rate of decline of CD4 cells or T cell responses from pre to post 
psychosocial group intervention. However, they report those subjects who showed larger 
decreases in distress showed a smaller decline in CD4 cell counts. 
In a comparison of the long term and immediate effects on immune function in 
patients with malignant melanoma, Fawzy et al. (1990) observed that patients receiving a 
6 week structured psychiatric group intervention showed improvement in affective state, 
coping, and the NK lymphoid cell response system. Intervention group patients had 
significant increases in the percent of large granular lymphocytes and natural killer cells 
along with indications of increase in NK cytotoxic activity; and a small decrease in 
percentage ofCD4+ T cells. Additionally they state affective rather than coping measures 
showed some significant correlations with immune cell changes. 
The reduction of mitogen-induced Ca2+ signals in T cells is felt to be a reliable 
state marker in depressive illness. Successful treatment with interpersonal psychotherapy 
has been shown to reverse this reduction (Aldenhoff et al., 1997). 
Udelman, (1983), in an overview ofpsychoimmunology, reports studies which 
have demonstrated suppression ofT and B lymphocytes for 6 months to a year in 
response to bereavement, correlation between degree of depression and suppressed 
chemiluminescence, as well as correlations between hope and T and B cell counts. The 
authors conclude adequate psychological defenses would be of aid in reducing 
vulnerability to illness and that the psychotherapist is confronted by a newly measurable 
challenge to aid in control of not only emotional, but also physical illness. 
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In conclusion there is conflicting evidence of a relationship between improved 
immune function and the provision of psychotherapy. In this clinical trial, an 
investigation of the effects of psychotherapy on immune function, particularly CD4+ T 
cells, was included only to observe trends. Before the start of the project, the researchers 
determined there would be insufficient sample size to adecquately study the relationship 
between psychotherapy and CD4 T cells. 
5.5 Strengths and Limitations 
The thesis study was designed, and powered, to examine the impact of 
psychotherapy on psychological parameters. It does not have adequate statistical power to 
detect an impact on markers ofHIV progression, such as CD4 cell counts. It would have 
been of interest to restudy the psychological parameters at a moderately long interval 
after the conclusion of the trial. The anticipated attrition of sample size and the resultant 
dilution of statistical power made this impractical. Similarly, the relatively high dropout 
rate seen in other studies like this presents analytical challenges. The author chose, in the 
first instance, to bolster the sample size in proportion to the anticipated attrition rate. In 
retrospect, the observed and expected attrition rates were similar. In the second instance, 
the author made the a priori decision to do supplementary analyses in which previous 
values were brought forward to replace missing values. The major conclusions were 
similar using both strategies. 
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There is limited evidence regarding the long-term effects of psychotherapeutic 
interventions to ameliorate depression in persons living with HIV and AIDS. This is 
partially due to insufficient sample size at the post intervention trial period. Where 
sample size may have been adequate at the start of the trial, losses by the end of the trial 
have presented analytical problems. In earlier trials, efficacious antiretroviral therapy 
was not readily available and many patients died or were too medically ill to permit 
follow-up assessments. Improvements in antiretroviral treatments have helped delay 
deaths and poor health and should help maintain sample sizes for long-term follow-up. 
A second problem in terms of patient follow-up, was that sufficiently large 
numbers of patients moved away from the study area, to larger centers, for reasons which 
included fear of ostracism by the community and a belief that more effective treatments 
were available outside the province. Increased acceptance has encouraged people to 
continue to live in their communities. Greater access and knowledge regarding drug 
management ofHIV has also encouraged HIV positive patients to remain in their 
communities. Changes such as these may help investigators maintain the power to 
investigate long-term effects of psychotherapy in the future. There is a need for RCTs 
with sufficient power to investigate the long-term effects of psychotherapeutic 
interventions on both psychological outcome measures and immune variables. A result of 
widely accepted HIV I AIDS management guidelines ensures reasonably similar 
comparison groups, making it more feasible to conduct multi-centered trials that can 
bolster sample size. 
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Many studies utilize group psychotherapy in order to achieve a balance between 
the numbers of people requiring the service and the increased time and monetary costs of 
delivering individual psychotherapy. There is evidence that psychological distress is 
reduced with the provision of group psychotherapy, at least for less psychologically ill 
populations. An important issue in the provision of psychotherapy is that many patients 
are uncomfortable, unwilling or unable to participate in group psychotherapy, and efforts 
to employ this model have led to increased psychological distress as well as direct 
refusal. 
In retrospect this study relied on the therapist being willing to be available to 
patients on 24-hour call for the duration of the trial. It would have been desirable to have 
at least two therapists providing the intervention. Funding was not available to employ 
two therapists. 
The introduction to this thesis highlighted the prevalence of HIV infection 
globally, nationally, and locally. It would be difficult to implement the psychotherapeutic 
model of this RCT on a global scale, or perhaps even a national scale. Most therapists 
would be unable or unwilling to provide weekly or biweekly therapy to more than 20 or 
30 patients. There would be insufficient therapists to treat the millions of people living 
with HIV I AIDS. In addition, the cost would be exorbitant, especially in the third world 
were money for food is often unavailable, and money for the provision of psychotherapy 
is unlikely to become available. Countries, such as Canada, with a national health plan 
could more easily provide similar interventions. For patients with private health 
insurance, or financial stability, it may be feasible to avail of routine psychotherapy. 
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However, it is possible to implement psychotherapeutic interventions as part ofHIV 
disease management in areas such as Newfoundland and Labrador and Labrador where 
the number of patients is relatively small. The cost to deliver the services available in this 
trial could be provided for $50,000.00 per year per therapist. 
Substantial costs have been associated with the treatment of psychological 
distress, not only in terms of medical management, but also in terms oflost productivity. 
Improved psychological function would likely lead to increased productivity for patients, 
thus reducing the financial burden. 
Further studies are needed to investigate the impact on immune function 
associated with the provision of psychotherapy. If conclusive evidence can be obtained 
demonstrating improved immune function there may be cost savings related to treating 
less medically ill patients. From patient self-reports and clinical team observations, 
patients in the psychotherapy group were more adherent to drug therapy than control 
patients, and appeared to be healthier and to require less clinic visits. It would not be 
difficult to study the impact of psychotherapy on utilization ofhospital and physician 
services, nor to investigate cost effectiveness of the provision of psychotherapy to 
persons with HIV infection. The possibility exists that interventions such as those 
discussed in this trial might lead to improved health of patients thus decreasing cost of 
care. Putting aside the issues of financial cost, one can argue that we are just as entitled to 
good psychological health as we are to good physical heath, and treatment of patients 
should focus on all aspects of care that contribute to the highest possible quality of life. 
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One explanation often put forward to explain the improvement on measures of 
depression and hopelessness is the increase in effectiveness and availability of 
antiretroviral medications. There are clear benefits of these medications in treating 
persons living with HIV and AIDS. However, if these medications were responsible for 
the improvement of psychological measures of distress then control subjects treated with 
similar medications, should improve along these measures also. In fact, by the 6-month 
point is this trial, control patients have higher measurable psychological distress than 
treatment subjects. This observation is seen again at the 12-month period. There is 
evidence from this trial, which is supported by other investigators, that the psychotherapy 
contributes to improvement in psychological well-being. 
A visual examination ofthe baseline characteristics of the study subjects revealed 
some differences which the author felt might be associated with the primary outcome. 
These differences, which included marital status, age, sexual orientation, gender, and 
route of transmission, were examined in order to assess their impact on the primary and 
secondary outcomes measures. None of these characteristics were found to be 
significantly associated with depression, hopelessness or CD 4 T cell counts. A 
statistically significant association was found with the 12- month CISS subscale 
avoidance, however this was clinically nonsignificant, as avoidance scale values for both 
treatment and control were in the same diagnostic category "average". Analyses that 
adjusted for the above baseline factors failed to change the study conclusions. These 
findings provide support for the conclusions that the improvements seen in depression 
and hopelessness were due to the psychotherapy. 
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5.6 Implications for Clinical Practice and Health Provider Education 
The findings related to depression and hopelessness reported in this thesis 
provides support for the provision of psychotherapy as part of the routine management of 
persons living with HIV and AIDS. It appears there is benefit to providing 
psychotherapy service to all HIV positive patients, not just when they are in crisis but as 
an ongoing intervention. The goal is to explore psychological deficits and promote skills 
training that empowers the patients to resolve issues before they reach crisis levels. 
There appears to be benefit to more formal screening to assess psychological dysfunction, 
which will permit earlier interventions. Additionally, a therapist as part of the clinical 
team, can provide information regarding the psychological well being of patients, training 
in early recognition by team members of symptoms ofpsychological dysfunction, skills 
building of team members which will enhance their ability to treat psychological deficits, 
as well as provide emotional support for other team members who are confronted with 
the psychological problems which often accompany HIV disease. 
Following this clinical trial, and in part, as a response to the outcomes observed, a 
psychiatrist who provides psychotherapy when required has now become a member of 
the HIV team meetings. In addition, the team, under the guidance of the psychiatrist, has 
implemented routine screening using the SCL-90-R (Derogatis, 1994). 
The results of this trial also suggest that there is a role for more in-depth training 
for all health care professionals concerning the psychological well-being of patients 
living with chronic illness such as HIV. This increased focus on the patients' 
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psychological well-being needs greater emphasis in the undergraduate curriculum of 
health professional schools and faculties within universities. Interdisciplinary education, 
which promotes the understanding of each discipline's role and the advantages of an 
interdisciplinary care approach while emphasizing mutual respect for all members of the 
team, should be provided at the earliest levels of each discipline's educational program. 
This therapist has become involved in health professional undergraduate 
education and has been assisting in the implementation of an interdisciplinary educational 
module involving nursing, social work, pharmacy and medical students. In postgraduate 
resident education, this psychotherapist has presented during academic half day for 
psychiatry residents and has consulted with psychiatrists and psychiatry residents on HIV 
patients. As a member of the HIV team the therapist has assisted in the development of 
province-wide interdisciplinary HIV clinics, which emphasize both the physical and the 
psychological management of the disease. This investigator has developed and 
participated in interdisciplinary CME events, which encourage the need for ensuring the 
psychological well-being ofHIV positive persons. In collaboration with the HIV care 
team this investigator has applied for, and received, industry funding to run 
interdisciplinary education sessions across the Province ofNewfoundland and Labrador. 
This investigator, in collaboration with faculty from pharmacy, nursing and social 
work, developed a health care provider needs assessment. This work was an extension of 
the ideas developed during the RCT and was funded by the Health Canada/ Association of 
Canadian Medical Colleges HIV Scholar in Residence program. In addition, this work 
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has led to presentations to Health Canada on interdisciplinary approaches to health care 
delivery. 
Interdisciplinary professional development remains a key issue. While new 
curricula are being developed to introduce interdisciplinary learning and care, traditional 
practices are being maintained in the community. In order for the new generation health 
care professionals to incorporate these patterns of practice in their future careers, clear 
functional models within current practice have to be established and maintained. 
Research is also needed to evaluate the impact of the changing practice patterns on 
patient care. 
5. 7 Conclusions 
An attractive feature of this trial was the heterogeneity of the subject sample. A 
wide range of depression and hopelessness scores was observed, and the subjects differed 
in terms of sexual orientation, gender, age, stage of illness and mode of disease 
transmission. The study sample represented a large proportion of the HIV positive 
population in Newfoundland and Labrador. These characteristics suggest the findings are 
generalizable. The study is, however, limited to a single centre, and a single therapist. It 
would be desirable to have a larger study, in multiple centres. The logistics of completing 
such a trial are challenging. Despite its limitations, however, this study suggests that 
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regular psychotherapy has a place in the day-to-day care of patients living with HIV 
infection. 
Traditionally, psychotherapeutic interventions are offered to patients when they 
show clear signs of depression or when they are in crisis. Study patients who continued to 
receive routine psychotherapy maintained depression scores which were not indicative of 
clinically significant depression. Patients receiving a crisis intervention model of delivery 
maintained significantly higher scores on measures of depression and hopelessness. A 
model of psychotherapy which provided for routine psychotherapy sessions appears more 
effective at reducing depression and hopelessness than a model of psychotherapy delivery 
only when the patient was thought to be in crisis. This conclusion is supported by the 
significantly lower depression and hopelessness scores observed in the intervention group 
subjects. The results of the RCT reported in this thesis suggests that crisis intervention, 
which focuses on immediate needs, does not empower the patient to develop strategies 
for dealing with episodes of depression and hopelessness that can follow a diagnosis of 
HIV infection. 
The real success of this clinical trial is not measured in changes in scores on 
psychological questionnaires or changes in lab values obtained from blood samples, but 
is the individual patients who were able to regain their autonomy and experience 
happiness, hope for their future, and relief from feelings of worthlessness. 
Brief statements regarding a few of the patients who were enrolled in this clinical 
trial helps demonstrate the efficacy of psychotherapy. One ofthe patients not only 
completed high school equivalency but also obtained a nursing degree. Another patient, 
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whose greatest regret was her inability to have children, was able, through therapy, to 
come to realize she has not only value as a person but also the skills to fulfill her dreams, 
and is deserving of them. She now has two healthy children and is a role model for 
successful autonomy. Another patient came to see that her beliefs that she was worthless 
and only deserved abuse, has left her abusive situation and has found successful 
employment and a new stable supportive relationship. A patient, for one of the very first 
times in his life, felt he could trust another person and asked for the therapist's support to 
end his life. He brought his child to therapy so that she could learn more about the finer 
qualities of her father and the implications ofhis death. One of the patients was able to 
work through so much repressed anger that he was able to reestablish a loving marriage 
that had been battered by the loss ofhis infant son to HIV. One of the patients, who 
experienced bi-weekly confrontations with the police, now has intervals of many months 
between police interventions and suicide attempts. A patient with a history of frequent IV 
drug use and prostitution was almost a year without IV drug use and participation in the 
sex trade. Currently, there is a substantive decrease in his IV drug use and prostitution. 
Another patient was able to find the self-respect to accept the truth that someone could 
love her. One patient learned to both talk to and trust his adoptive parents. This patient 
acquired self-respect and came to believe he had entitlement to more than just abusive 
relationships. 
These are only a very few of the many stories of patients achieving autonomy and 
happiness through psychotherapeutic support, and reinforces the evidence that 
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psychotherapy helps improve the lives of those people confronted with the challenges of 
living with HIV and AIDS. 
From a personal perspective, this researcher has no regrets related to the demands 
of this research project. Working with HIV patients has been, and continues to be, an 
extremely humbling experience. I have witnessed incredible triumphs in the quest to find 
happiness in a world that was oftentimes cruel, frightening and bleak. I have witnessed 
laughter from patients, whose physical pain is beyond the scope of most peoples' 
experiences. I have watched people recapture their autonomy after periods of total 
hopelessness and desires to be dead. I can only hope that my experience with people 
living with HIV/AIDS has made me a more understanding, gentler and giving person. 
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Appendix A 
Patient Consent Form 
FACULTY OF MEDICINE 
MEMORIAL UNIVERSI'IY OF NEWFOUNDLAND 
ST. JOHN'S, NEWFOUNDLAND AlB 3V6 
CONSENT TO PARTICIPATE IN BIO-MEDICAL RESEARCH 
TITLE: The Effect of Psydl.ological Counselling in Patients with HIV/AIDS 
OFFICIAL TITLE: EFFICACY OF PSYCHOTHERAPY IN HIV/AIDS 
INVESTIGATOR(S): M. Ian Bowmer, J.E.G. Mugford, Constance Campbell 
Your doctor will already have asked you if you would be willing to take part in this study. 
The purpose of this form is to explain the study and then record your consent if you decide 
to take part. 
Purpose of study: 
Previous research in chronic illness shows that providing psychological counselling support 
may reduce hospital admissions and patient visits. This study is designed to examine the 
effectiveness of providing psychological counselling support to people with HIV/AIDS. 
Description of prooodures and tests: 
You understand that if you agree to enter the study, you will have a 50:50 chance of 
receiving counselling. If you are assigned to the counselling group then the frequency of 
counselling will be determined by you and your counsellor. You understand that the 
counselling sessions will be a time commitment above and beyond your routine clinical 
visits. Each meeting with the counsellor will be scheduled for one (1) hour. You understand 
that counselling is not normally ended abruptly and that a schedule of reduced frequency 
of visits will be developed with the counsellor as the end of the study is approached. 
Your participation in the study means you will complete three standard psychological test s 
which will help measure your level of depression, self esteem and ability to cope. (THESE 
TESTS ARE NOT USED TO MEASURE INTELLIGENCE). These tests will occur at the 
beginning of the study and at approximately three month intervals until the end of the 
study. Testing time is approximately one hour and your counsellor will try to schedule 
these tests during your regular clinic visits. 
Revised October 6, 1995 1 
Patient's Initials: -------
Date: ----------
Foreseeable risks, discanforts, or inoonveniences: 
You understand that stopping counselling abruptly may cause anxiety. Inconveniences will 
include the time spent completing the psychological questionnaires and the time required 
to attend the counsellimg sessions. 
Benefits which the subject may receive: 
You understand that while it is possible that there may be no benefit to you, your 
participation in this study may help others with HIV/AIDS. 
Alternative treatment for th~e not entering the study: 
All routine care and support will be available to you if you choose not to enter the study. 
Confidentiality: 
Documentation of your participation in this study will be permanently included in your 
health record at the General Hospital and your hospital chart will be viewed by the study 
investigators. 
l-nless required by law or hospital policy, only your doctor, the counsellor, and the HIV Co-
nrdinat or may have access to your General Hospital health record or any confidential 
·locumL·nts pertaining to your participation in this study that may identify you by name. 
This :1ccess will only be permitted in the presence of the researcher or one of his 
i"<' !H'Psvnt ~Hives. Furthermore your name will not appear in any report published as a result 
.t t hi :-; .-.,t ud \' . 
\ 'oluntan: participation in the study: 
Your participation in this study is voluntary. You may refuse to participate or may 
\\"ithdra \\' 3t any time during the study, without any penalty or prejudice to the quality of 
the medical care you may require in the future. Furthermore, your physician may require 
you to be withdrawn without your consent if you do not respect the study protocol. 
Liability statement: 
Your signature on this form indicates that you have understood to your satisfaction the 
information regarding your participation in the research project and agree to participate as 
a subject. In no way does this waive your legal rights nor release the investigators, 
sponsors, or involved institutions from their legal and professional responsibilities. Funding 
for this project comes from the General Hospital and Health Canada. 
Revised Oc tob er 6. 1995 2 
Patient's Initials: --------
Date: ----------------------
I, ______________ __, the undersigned, agree to my participation or to the 
participation of (my child, ward, relative) in the research study 
described. 
Any questions have been answered and I understand what is involved in the study. I 
realize that participation is voluntary and that there is no guarantee that I will benefit from 
my involvement. I acknowledge that a copy of this form has been given to me. 
(Signature of Participant) (Date) 
(Witness Signature) (Date) 
To be signed by investigator: 
To the best of my ability I have fully explained to the subject the nature of this research 
study. I have invited questions and provided answers. I believe that the subject fully 
understands the implications and voluntary nature of the study. 
(Signature of Investigator) (Date) 
Phone Number: 
If Appropriate: 
(Signature of Minor Participant) 
(Age_) 
Relationship to Participant Named Above _ _ _ 
Revised:October 6, 1995 
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scanned at the request of the author. They are available for 
consultation in the author's university library. 
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